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1. Introduction  
1.1  Diabetes and hyperglycaemia 
Diabetes became a major epidemic of this century with rapidly increasing incidence 
worldwide (Forbes and Cooper, 2013).  Diabetes is clinically characterised by chronic 
elevation of blood sugar, termed “hyperglycaemia”. There are two major types of diabetes: 
type 1 diabetes (T1D) and type 2 diabetes (T2D), although diabetes can also manifest during 
pregnancy (gestational diabetes) (Forbes and Cooper, 2013). In type 1 diabetes, 
hyperglycaemia is the result of autoimmune reactions destroying pancreatic beta cells 
producing insulin. In type 2 diabetes, which is much more common, hyperglycaemia is the 
result of progressively impaired glucose regulation due to a combination of insulin resistance 
in certain organs and dysfunction of pancreatic beta cells (Lewis et al., 2014). Diabetes is 
associated with a number of macro- and microvascular complications leading to the failure of 
organs such as the heart, kidneys and eyes (Beckman and Creager, 2016; Cade, 2008). It is 
widely accepted that achieving optimal glycaemic control as early as possible in the course of 
the disease is the most effective way to reduce the risk of vascular complications in both type 
1 and type 2 diabetes (Forbes and Cooper, 2013).  
1.1.1 Type 1 diabetes: autoimmune disease 
In type 1 diabetes, a complex interplay between genetic and environmental factors leads to the 
autoimmune reactions resulting in the destruction of insulin-producing beta cells in pancreatic 
Langerhans islets (Forbes and Cooper, 2013; Simmons et al., 2016).  The incidence of T1D is 
increasing in westernised societies, and it is mostly diagnosed in young children (Roep and 
Tree, 2014; Simmons et al., 2016). The genetic basis of T1D includes specific determinants in 
the major histocompatibility complex locus (HLA), however the specific HLA determinants 
can explain only about 50% of the familial clustering of T1D (Forbes and Cooper, 2013). The 
development of T1D involves many immune cells; CD4+ and CD8+ T cells, as well as 
macrophages are major immune cell types that mediate beta cell destruction by autoantigen-
specific inflammatory mechanisms (Lehuen et al., 2010). Glutamic acid decarboxylase 
(GAD/GAA), and protein tyrosine phosphatase (IA-2AA) are the most common autoantigens 
involved in the process of beta cell destruction. A study by Pardini et al. demonstrated that 
GAD frequency was higher compared to IA-2 in Brazilian T1D patients (Pardini et al., 1999).  
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1.1.2 Type 2 diabetes: metabolic disease 
Type 2 diabetes is caused by a complex interplay between insulin resistance, beta cell 
dysfunction, and a relative lack of insulin (Jeffery and Harries, 2016). Insulin resistance is 
most frequently detected in muscle, liver and adipose tissue due to the intensive glucose 
uptake for metabolism in these tissues (Forbes and Cooper, 2013). Obesity is one of the 
causes of insulin resistance leading to the development of T2D (Saltiel and Olefsky, 2017). 
Adipose tissue (AT) is composed of adipocytes, pre-adipocytes and a high number of 
macrophages, that can develop pro-inflammatory phenotypes (M1-like phenotype) in 
response to metabolic factors (Espinoza-Jiménez et al., 2012). As a result, obesity leads to 
increased production of inflammatory cytokines such as TNF-alpha, IL-1beta, IL6 and CCL2, 
as well as reactive oxygen species (ROS) in fat tissue, resulting in obesity-associated low-
grade inflammation (Lackey and Olefsky, 2016). In turn, low-grade inflammation can lead to 
insulin resistance and development of T2D as a consequence (Espinoza-Jiménez et al., 2012; 
Lackey and Olefsky, 2016). It was demonstrated that in both in-vivo and in-vitro models that 
exposure of adipocytes to hyperglycaemia leads to insulin resistance (McArdle et al., 2013). 
Furthermore, blocking of pro-inflammatory signalling pathways involving JNK and TNF-
alpha contribute to obesity-related insulin resistance improvement (Eguchi and Manabe, 
2013; Hotamisligil, 2006). Insulin resistance can be accompanied by compensatory 
hypersecretion of insulin by pancreatic islets that may precede a decline in beta cell functions. 
However, it appears that at later stages, insulin secretory defects are a critical parameter in the 
ultimate development of T2D (Forbes and Cooper, 2013).  
1.2 Vascular complications of diabetes 
Diabetes mellitus is associated with the development of long-term vascular complications that 
include microvascular and macrovascular complications. Microvascular complications 
include retinopathy, nephropathy and neuropathy, while major macrovascular complications 
include cardiovascular and cerebrovascular diseases (Forbes and Cooper, 2013).  
 
Several studies have shown that hyperglycaemia is a critical factor for the development of 
microvascular and macrovascular complications in type 1 and type 2 diabetes (Schalkwijk and 
Stehouwer, 2005; van Diepen et al., 2016). However, other factors such as age, smoking, 
obesity, hypertension, hyperhomocysteinaemia, hypercholesterolaemia and dyslipidemia have 
a significant contribution to the damage to the vascular wall and lead to endothelial 
dysfunction (Caballero, 2003; Martin-Timon et al., 2014; Schalkwijk and Stehouwer, 2005). 
Moreover, development of diabetic vascular complications is a result of a complex interplay 
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between metabolic and inflammatory pathways affecting not only endothelial cells, but also 
various somatic and immune cells.  
  
1.2.1 Microvascular complications 
Microvascular complications of diabetes affect small blood vessels. Hyperglycaemia is 
considered to be the main causative agent for microvascular complications. The risk of 
microvascular complications depends on the level and duration of the hyperglycaemic 
condition (Forbes and Cooper, 2013). Major microvascular complications include diabetic 
retinopathy, nephropathy and neuropathy and are described in following paragraphs.  
 
Diabetic retinopathy 
One of the most commonly affected organs in microvascular complications are the eyes.   
According to the U.K. Prospective Diabetes Study (UKPDS), development of diabetic 
retinopathy in type 2 diabetic patients was found to correlate with both severity of 
hyperglycaemia and the presence of hypertension (Davis et al., 1999). In most cases, type 1 
diabetic patients developed retinopathy within 20 years of diagnosis (Keenan et al., 2007). 
Degeneration or occlusion of retinal capillaries is indicative of a worsening prognosis of 
retinopathy (Forbes and Cooper, 2013). There are many pathological mechanisms by which 
diabetes leads to the development of retinopathy. 
 
Aldose reductase can contribute to the progression of diabetic complications (Tang et al., 
2012). Aldose reductase is the enzyme involved in the polypol pathway that regulates the 
conversion of glucose into sorbitol. Hyperglycaemic states lead to increased accumulation of 
sorbitol in the cells. Accumulation of sorbitol leads to osmotic stress resulting in the 
progression of diabetic microvascular complications, including diabetic retinopathy (Fowler, 
2008; Keenan et al., 2007; Sorrentino et al., 2016; Vedantham et al., 2012).  
 
Oxidative stress plays an important role in cellular injury in response to hyperglycaemia. 
Hyperglycaemia stimulates free radical production and ROS formation that leads to the injury 
of endothelial cells. In mouse models, treatment with antioxidants, such as vitamin E, is 
shown to reduce some vascular dysfunctions linked with diabetes (Keenan et al., 2007; 
Sorrentino et al., 2016). 
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Hyperglycaemia can induce the formation of advanced glycosylated end products (AGEs), 
which interact with RAGE receptor leading to the activation of NF-kB-mediated 
inflammatory responses in endothelial cells and macrophages (Bierhaus and Nawroth, 2009). 
It was suggested that hyperglycaemia-induced activation of inflammatory responses in retinal 
endothelial cells, as well as in Müller cells, astrocytes, ganglion cells and microglial cells, is a 
central process that integrates vasculopathy and neuro-inflammation at the level of 
neurovascular damage leading to diabetic retinopathy (Yu et al., 2015). Major inflammatory 
molecular players produced as a consequence of hyperglycaemic conditions include cytokines 
and growth factors (VEGF, IL-1beta, CCL2, TNF-alpha, IL6) (Yu et al., 2015). However, 
especially for microglial cells, which represent resident macrophages in the retina, the 
identified pro-inflammatory effects were rather mediated by AGE, and the direct effect of 
hyperglycaemia on cell activation remains to be identified.  
 
Diabetic nephropathy 
Diabetic nephropathy is the leading cause of kidney failure in the United States.  It is defined 
as proteinuria > 500 mg/24 hours or albumin excretion of 30-299 mg/24 hours in the diabetic 
condition (Josipovic et al., 2013). Diabetic patients with microalbuminuria normally progress 
to diabetic nephropathy. Diabetic nephropathy can occur in both type 1 and type 2 diabetes 
(Beckman and Creager, 2016; Josipovic et al., 2013). The pathological changes in the kidney 
include increased glomerular basement membrane thickness, microaneurysm formation and 
mesangial nodule formation. Hyperglycaemia affects several resident cell types in the kidney, 
including endothelial cells, smooth muscle cells, mesangial cells, podocytes, and cells of the 
tubular and collecting ducts system, immune cells and myofibroblasts. The hyperglycaemia-
induced pathological processes in diabetic nephropathy can be similar to that in diabetic 
retinopathy including losing control of energy production, activation of the aldose reductase 
pathway and induction of pro-inflammatory reactions (Forbes and Cooper, 2013; Wada and 
Makino, 2016). It was also recently recognised that hyperglycaemia is an essential factor in 
the activation of the NLRP3 inflammasome during the development of diabetic nephropathy 
(Qiu and Tang, 2016). The NLRP3 inflammasome is responsible for the conversion of the 
pro-inflammatory cytokines IL-1beta and IL18 to their active forms, and targeting of the 
NLRP3 inflammasome was suggested as a promising therapeutic strategy (Hutton et al., 2016; 
Qiu and Tang, 2016).  
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Diabetic neuropathy 
The risk of developing diabetic neuropathy depends on both the magnitude and duration of 
hyperglycaemia, and genetic factors can contribute to a predisposition (Fowler, 2008). The 
possible mechanisms involved in hyperglycaemic progression of neuropathy include polyol 
accumulation, injury from AGEs and oxidative stress. In diabetic neuropathy, more than 80% 
of amputations occur after injury or foot ulceration (Fowler, 2008). Diabetic neuropathy 
causes major sickness and mortality in patients with diabetes. The primary treatment of
 
diabetic neuropathy is to control the hyperglycaemic conditions (Beckman and Creager, 
2016). Persistent hyperglycaemia is believed to be an essential factor leading to 
neuroinflammation and nerve damage (Sandireddy et al., 2014b). Polyol, PKC, the MAPK 
pathway, as well as an increase in the formation of AGE, can all have direct or indirect effects 
on the activation of inflammatory processes in diabetic neuropathy. Persistent hyperglycaemia 
affects structural features on neurones leading to the recruitment of monocytes and 
macrophages. Accumulating AGE acts on the spectrum receptors present on microglia and 
newly recruited macrophages, and stimulates the production of pro-inflammatory cytokines 
(including IL1, IL6, TNF-alpha, CCL2) that exert pathological effects on endothelial cells and 
neurones (Sandireddy et al., 2014b; Wada and Yagihashi, 2005).  
 
1.2.2 Macrovascular complications 
Macrovascular complication affects major arteries leading to the development of 
atherosclerosis; a complex chronic inflammatory disease involving the pathological action of 
numerous cell types. The dysfunction within endothelium in diabetic conditions seems to be a 
key early factor contributing to the initiation of atherosclerosis (Bertoluci et al., 2015).  
Development of atherosclerosis is considered to be a consequence of low-grade inflammation 
of the arterial walls where both endothelial cells and monocytes/macrophages are 
pathologically programmed by metabolic factors including hyperglycaemia (van Diepen et al., 
2016). Macrophages are key innate immune cells that contribute to the formation and 
progression of atherosclerotic plaque. Several processes are essential for the progression of 
atherosclerosis including intensive infiltration of monocytes into subendothelial space, 
differentiation of monocytes into pathological macrophage phenotypes, deficiency in 
degradation of the internalised lipoproteins, and defects in cholesterol efflux resulting in foam 
cell formation (Kzhyshkowska et al., 2012). Macrophage scavenger receptors play a role in 
the pathological processing of modified lipoproteins leading to the formation of foam cells 
(Kzhyshkowska et al., 2012). Recently, it was shown that loss of IGF-1 (insulin growth 
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factor) signalling drives pro-inflammatory macrophages and increases lipid accumulation in 
macrophages (Higashi et al., 2016). Foam cells stimulate the attraction of T-lymphocytes 
which in turn stimulate smooth muscle cell proliferation in the arterial walls leading to the 
accumulation of collagen and the formation of a lipid-rich atherosclerotic lesions; 
atherosclerotic plaques, covered with a fibrous cap. The breaking of these lesions direct to 
acute vascular infarction (Boyle, 2007; Fowler, 2008). Hyperglycaemia is an essential factor 
in the development of macrovascular complications, since a significant long-term controlled 
study demonstrated that improved hyperglycaemic control in type 2 diabetic patients leads to 
a decreased incidence of macrovascular diseases (Fowler, 2008). Hyperglycaemia was 
identified as an independent risk factor for cardiovascular diseases (CDV). Even transient 
hyperglycaemia upon return to normoglycemia increases the risks of CVD, a phenomena 
named “hyperglycaemic memory”.  Long-term epigenetic programming of monocytes and 
macrophages was suggested to be critical for hyperglycaemic memory resulting in diabetes-
associated CVD (van Diepen et al., 2016).  
 
1.3 Hyperglycaemia links oxidative stress and inflammation 
Hyperglycaemia activates both oxidative stress and inflammatory pathways resulting in the 
pathological activation of a number of cell types that mediate progression of diabetes and 
vascular complications (Sandireddy et al., 2014a). Hyperglycaemia induces the generation of 
superoxide anions by increasing metabolic flux through the mitochondrial electron transport 
chain that in turn results in the production of ROS (Brownlee, 2005; Sandireddy et al., 
2014a). ROS has the ability to damage DNA, proteins and lipids facilitating endothelial cell 
injury leading to vascular complications. ROS can also activate the NF-kB and JNK mediated 
inflammatory pathways that are crucial for inducing insulin resistance and dysfunction of beta 
cells (Evans et al., 2003). 
 
Oxidative stress produced by hyperglycaemia activates Nrf2, NF-kB and MAPK mediated 
signalling pathways (Sandireddy et al., 2014a) (Figure 1).  Activation of the Nrf2 pathway is a 
natural homeostatic mechanism that protects the cells from oxidative stress and inhibits NF-
kB activation (Sandireddy et al., 2014a; Tan et al., 2011) (Figure 1). However, Nrf2 activation 
in hyperglycaemic conditions is attenuated by the activated ERK pathway. ROS activates the 
inhibitory kappa-B kinase (IKK), which mediates phosphorylation of IkB and causes 
proteasomal cell death (Tan et al., 2011).  Released from IkB, free NF-kB heterodimers 
translocate to the nucleus and activate transcription by  binding the kappa region of the 
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genome, which leads to the production of inflammatory cytokines such as TNF-alpha, IL6, 
iNOS and COX2 (Figure 1) (Cameron and Cotter, 2008; Sandireddy et al., 2014a). 
Hyperglycaemia can also directly or indirectly activate p38 MAPK which facilitates the 
activation of NF-kB in the cytoplasm (Figure 1) (Sandireddy et al., 2014a).  Moreover, 
oxidative stress activates c-Jun N-terminal kinases (JNK) leading to increased production of 
MCP-1, TGF-beta and collagenase, which mediate pro-inflammatory and pro-fibrotic 
reactions  (Figure 1) (Karin, 1995; Sandireddy et al., 2014a; Sutariya et al., 2016; Takaishi et 
al., 2003). Hyperglycaemia-mediated activation of the JNK, NF-kB and p38 MAPK pathways 
leads to the development of chronic inflammation and cellular damage, and is responsible for 
the development of late diabetic complications (Matough et al., 2012). Additionally, 
hyperglycaemia-dependent ROS induces the activity of methyltransferase Set7/9 in 
endothelial cells which is responsible for monomethylation of histone 3 lysine 4 (H3K4me1) 
(Paneni et al., 2013). The presence of H3K4me1 on the promoter region of NF-kB subunit 
p65 associates with the development of vascular complications (Paneni et al., 2013). Despite 
intensive investigation of the pro-inflammatory effects of hyperglycaemia, most mechanistic 
studies are limited to various types of endothelial cells. However, both the initiation and 
resolution of inflammation in the organism are under the precise control of the innate immune 
system, where macrophages are key immune cells in the local tissue microenvironment in 
virtually all organs and tissues that orchestrate inflammatory responses. 
 
1.4 Origin and differentiation of macrophages 
Macrophages are mature functional cells of the mononuclear phagocyte system which 
includes bone marrow monoblasts, pro-monocytes, peripheral blood monocytes and tissue 
macrophages (Embleton, 2003). The differentiation of bone marrow precursors to 
macrophages includes the following steps: committed progenitor cell – monoblast - pro-
monocyte - monocyte (bone marrow) - monocyte (peripheral blood) - macrophage (tissues). 
Resident macrophages have tissue-specific phenotypes and historically can also have tissue-
specific names, like microglial cells in the neuronal system and eyes, histiocytes in the 
connective tissue, osteoclasts in bones and Kupfer cells in the liver. Mature tissue 
macrophages are characterised by the expression of different proteins including CD14, 
CD11b, F4/80 (mice)/EMR1(human), CD68, lysozyme M, CSF-1R and  MAC-1/MAC-3, 
(Hume, 2006; Taylor et al., 2005). However, it was later recognised that resident tissue 
macrophages can also derive from yolk-sac during early developmental stages (Gordon and 
Taylor, 2005). Later in development, the foetal liver can generate a next wave of macrophage 
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precursors populating the tissues during development of the embryo (Gordon and Taylor, 
2005). Therefore, monocyte-derived macrophages are not the primary macrophages in the 
tissue, but rather constitutively replace resident macrophages in adult organisms (Gordon and 
Taylor, 2005). A summary of the origin and major differentiation steps of macrophages is 
presented in Figure 2 (Gordon and Taylor, 2005). 
 
 
Figure 1.  Mechanisms that link hyperglycaemia and inflammation.  Reprinted from distributed 
under the Creative Commons Attribution-Non-Commercial License (Sandireddy et al., 2014a). 
 
Most recently the details of macrophage origin during the developmental stage were 
identified. Primitive yolk sac macrophages originate from early EMPs (erythroid-myeloid 
progenitors, E7.5) and, after blood in circulation is initiated, primitive macrophages populate 
various peripheral organs (Hoeffel et al., 2015; Schneider and Kopf, 2015) (Figure 3). The 
next wave of EMPs (around E8.5) migrate into the liver, where part of them differentiate into 
foetal monocytes. From E13.5, foetal monocytes colonise the majority of organs where, under 
stimulation with specific microenvironment factors, they differentiate into resident tissue-
specific macrophages. However, microglia directly derive from early primitive macrophages, 
but not from foetal monocytes (Hoeffel et al., 2015; Schneider and Kopf, 2015). There is also 
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evidence that tissue-specific macrophages can proliferate and self-renew, however, the 
contribution of this self-renewal process compared to the contribution of newly infiltrating 
adult bone marrow derived monocytes is an open question that is under intensive 
investigation (Rosas et al., 2014).  
 
Specific transcription factors are responsible for determining function and adoption of tissue-
specific macrophages. For example, microglial cells  (brain resident macrophages) express 
Sall1 and mef2c (Schlitzer and Schultze, 2016).  PPARγ and BACH2 have been recognised to 
control alveolar macrophage population function and fate (Nakamura et al., 2013; Schlitzer 
and Schultze, 2016; Schneider et al., 2014). In adipose tissue, macrophages play a major role 
in crosstalk between white adipose tissue cells and the immune system (Castoldi et al., 2015; 
Schlitzer and Schultze, 2016). During obesity, more bone marrow derived monocytes are 
recruited to the fat that programs them towards a pro-inflammatory M1 phenotype (Lumeng 
et al., 2007).  
 
Figure 2. Origin and major differentiation steps of cells of the mononuclear phagocyte system in 
a mouse. Permission obtained from Copyright Nature Publishing Group (Gordon and Taylor, 2005). 
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Figure 3. Development of primitive macrophages and foetal monocytes from erythro-myeloid 
progenitors (EMP) in the Yolk Sac. Permission obtained from Copyright Elsevier (Schneider and 
Kopf, 2015). 
 
1.4.1   Classification of macrophages and activation  
Depending on the wide range of microenvironmental factors, macrophages can differentiate 
into different types of macrophages. The original concept of macrophage activation 
considered macrophages as effectors of Th1 and Th2 cells, and defined major macrophage 
types as classically (M1) and alternatively (M2) activated. Correspondingly, two major 
cytokines, IFNg produced by Th1 cells, and IL4 produced by Th2 cell, were found as major 
drivers for the M1 and M2 types of macrophages activation (Goerdt and Orfanos, 1999; 
Gordon and Martinez, 2010; Gratchev et al., 2001). M1 macrophages play a key role in the 
defence mechanism against bacterial pathogens by producing lysosomal enzymes, reactive 
oxygen species (ROS) and nitrogen species (NO)
 
(Ding et al., 1988). Cytokines released by 
classically activated macrophages are TNF-alpha, IL-1beta, IL6 and IL12 (Van Ginderachter 
et al., 2006). These cytokines can induce inflammatory and cytotoxic responses, and can 
activate NK cells, CD8+ cytotoxic lymphocytes and the recruitment of neutrophils.  
 
M2 macrophages comprise a different subpopulation that functions in tissue homoeostasis, 
resolution of inflammation and healing. M2 macrophages have increased clearance potential, 
express high levels of phagocytic and endocytic receptors, secrete a wide range of cytokines, 
growth factors, structural components of extracellular matrix and matrix-remodelling 
enzymes (Kzhyshkowska et al., 2016; Martinez and Gordon, 2014a). Major stimuli that 
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induce M2 polarisation, besides IL4, include glucocorticoids and TGF-beta (Figure 4). M2 
macrophages can also have detrimental functions by stimulating allergic reactions, pro-
fibrotic processes and tumour progression (Kzhyshkowska et al., 2016). More recently the 
concept of macrophage activation underwent further revision, and macrophages were 
classified according to a variety of stimuli resulting in the development of distinct phenotypes 
(Murray et al., 2014). However, the M1 and M2 classification remains to be a frequently used 
and convenient tool for distinguishing major types of macrophage functional polarisation, 
especially in different types of pathologies, including obesity and atherosclerosis. Mature 
macrophages were identified to be also highly plastic cells that can change their molecular 
profiles and functional phenotypes in response to secondary stimuli and a changing 
microenvironment (Kzhyshkowska et al., 2016; Mantovani et al., 2013). This functional 
plasticity of macrophages makes them an attractive target for therapy of chronic inflammatory 
diseases and cancer (Mantovani et al., 2013).  
 
 
Figure 4. Molecular markers and major functions identified for human monocyte-derived 
macrophages ex vivo. Each specific stimuli induces a specific molecular profile during monocyte to 
macrophages differentiation in culture conditions. The molecular profiles are indicative of the major 
functional activities of macrophage subtypes. Permission obtained from Copyright © 2016, Karger 
Publishers (Kzhyshkowska et al., 2016). 
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1.4.2    Functions of macrophages during acute and chronic inflammation 
Macrophages are key tissue resident cells that sense trauma or pathogen attack and initiate 
acute inflammation, which is a natural host defence mechanisms. During acute inflammation, 
macrophage actively kills pathogens and attracts other immune cells, including neutrophils 
and monocytes, to amplify the inflammatory reaction and eliminate pathogens. Macrophages 
also attract cells of the adaptive immune system that mediate antigen-specific responses to the 
pathogens. In response to bacterial infection, activated macrophages secrete a broad range of 
pro-inflammatory cytokines and chemokines (IL1, TNF-alpha, CC and CXC chemokines), a 
number of reactive oxygen intermediates and reactive nitrogen intermediates that have potent 
antimicrobial activity. These biologically active substances initiate the process known as 
inflammation (Duffield, 2003; Szekanecz and Koch, 2007).  
After the acute phase where the exogenous danger is eliminated and inflammatory reactions 
are not needed anymore, macrophages initiate resolution of inflammation and a healing phase 
that leads to the restoration of homeostatic tissue-specific balance. However, not completely 
eliminated pathogens (for example, residual virus infection), foreign bodies (like an implant) 
or endogenous factors (cytokines, fatty acids, AGEs) can drive local chronic inflammatory 
reactions that are characterised by imbalances in immune cell infiltration and activation 
(Murakami and Hirano, 2012).  
1.4.2.1 Chemotaxis  
Chemotaxis is an essential process in the course of both acute and chronic inflammatory 
reactions. Chemotaxis of different types of immune cells is strongly activated by chemokines 
produced locally by the inflamed tissue (Embleton, 2003). Resident monocytes continuously 
patrol the intravascular space (Kamei and Carman, 2010a). In the case of acute inflammation, 
inflammatory stimuli, including chemical irritants, aseptic wounding, and infection agents, 
induce rapid recruitment of patrolling monocytes. Initial monocyte infiltration precedes 
neutrophil accumulation by at least 1 hour (Kamei and Carman, 2010a). During acute 
inflammation, circulating neutrophils are actively recruited to the sites of tissue damage by 
several types of factors including leukotrienes (LTB4), complement factors (C5a), bacterial 
products and chemokines (Jones, 2000). During chronic inflammation (including 
atherosclerosis), there is a constant requirement of monocytes and T-cells that produce 
unbalanced amounts of pro-inflammatory mediators that interfere with the resolution of 
inflammation (Lindholt and Shi, 2006) (Zernecke et al., 2008). When leukocytes sense a 
chemoattractant, such as CCL2, CCL5 etc., and move directionally by changing the 
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cytoskeleton rearrangements, they form pseudopods and change cell shape. Chemoattractants 
activate leukocytes to bind to the endothelial cell surface and move across the cell layer 
towards the site of inflammation (Embleton, 2003). During obesity, adipose tissue secretes 
several adipokines (chemokines, cytokines and hormones) that include CCL2, TNF-alpha, 
IL1, IL6 and IL8 (Hotamisligil et al., 1993; Jung and Choi, 2014).  These inflammatory 
cytokines and chemokines attract monocytes into the fat tissue and stimulate the formation of 
the pro-inflammatory M1 phenotype, which in turn contributes to the development of insulin 
resistance (Jung and Choi, 2014; Xu et al., 2003).  
 
 
Figure 5. Structures of CCR2 and CCL2 (monocyte chemoattractant protein [MCP]-1).  
Permission obtained from Copyright John Wiley and Sons (Yamasaki et al., 2012).  
Major receptors that respond to chemotactic factors on monocytes include CCR1, CCR2, 
CCR5, CCR6, CCR7, CCR8, CX3CR1 and CXCR2 (Shi and Pamer, 2011).  CCR2 is the 
best-investigated receptor that is expressed not only on monocytes, but also on endothelial 
cells, T lymphocytes, B lymphocytes, natural killer cells, basophils and dendritic cells 
(Salcedo et al., 2000) (Yamasaki et al., 2012). CCR2 ligands include CCL2 (MCP1), CCL7 
(MCP3), CCL8 (MCP2), CCL13 (MCP4) and CCL16 (Yamasaki et al., 2012).  Studies 
demonstrated that hyperglycaemia induces the production of CCL2, CCL5 and CCL11 in type 
1 diabetic patients (Jamali et al., 2013; van der Torren et al., 2016). CCR2 is a seven 
transmembrane protein consisting of 3 extracellular and 3 intracellular loops, an extracellular 
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N-terminus, and a C-terminal cytoplasmic tail (Figure 5). The ligands bind to the extracellular 
N-terminal region. The 3 extracellular regions are also important for triggering intracellular 
reactions (Yamasaki et al., 2012). However, little is known about the effect of diabetic 
conditions on the expression of chemokine receptors on immune cells.  
  
1.4.2.2 Transmigration in inflammatory conditions 
In inflammatory conditions, endothelial cells overexpress P and E selectins that mediate cell 
rolling, signalling and chemotaxis of leukocytes (Barthel et al., 2007; McEver, 2015). 
Selectin-mediated adhesion and signalling were  shown to contribute to various vascular 
pathologies including atherosclerosis, arterial and deep vein thrombosis, ischaemia-
reperfusion injury, and other cardiovascular diseases (McEver, 2015). Selectins interact with 
glycoprotein ligands on the surface of recruited immune cells allowing leukocytes to bind 
weakly to vascular endothelium and initiate the adhesion cascade  (Somers et al., 2000). In 
inflammatory conditions (both acute and chronic), stromal cells, leukocytes and endothelial 
cells produce various chemokines (CC-and CXC-chemokines) and chemotactic compounds, 
such as leukotriene B4 (LTB4), platelet-activated factor (PAF) and N-formyl-methionyl-
leucyl-phenylalanine (fMLP), which stimulate rolling of leukocytes (Murdoch and Finn, 
2000). Chemokines bind to seven-transmembrane spanning G-protein-coupled receptors 
(GPCRs) expressed by leukocytes and induce rapid integrin activation (Ley et al., 2007; 
Murdoch and Finn, 2000). Activated surface molecules integrin-β1 and integrin-β2 promote 
tight adhesion of monocytes to the vessels via vascular cell-adhesion molecule 1 (VCAM-1) 
and intercellular adhesion molecules (ICAMs), and induce migration (Kim et al., 2003; 
Thelen, 2001). Monocytes are polarised via an atypical protein kinase C signalling pathway 
and form lamellipodium (Kamei and Carman, 2010b). They move along the luminal side of 
vascular endothelial cells and transmigrate in a paracellular or transcellular manner (Kamei 
and Carman, 2010b). During paracellular trans-endothelial migration of polarised leukocytes, 
platelet/endothelial cell-adhesion molecule-1 (PECAM-1) mediates the interaction between 
migrating cells and endothelial cells. PECAM is expressed on the surfaces of transmigrating 
monocytes and concentrated on the borders of endothelial cells. Integrins expressed on 
transmigrating leukocytes interact with ICAMs, VCAM-1 or junctional adhesion molecules 
(JAMs) on the surface of endothelial cells. In response to cytokines, TNF-alpha and INFg 
inflamed endothelium redistributes JAM-A molecules from the intercellular junctions to the 
luminal surface of the cells (Ozaki et al., 1999). Downregulation of tight junction molecule 
VE-cadherin contributes to the resealing of the junctions between the endothelial cells (Ley et 
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al., 2007). Endothelial junctional molecules can guide liminal leukocytes to the junctions and 
also actively mediate trans-endothelial migration (Ley et al., 2007). Interference with the 
transmigrating process has been considered as a therapeutic strategy in vascular diseases. For 
example, P-selectin is a critical molecule for the interaction of monocytes with activated 
endothelium during the progression of atherosclerosis, and targeting of P-selectin was 
suggested for treatment of atherosclerosis (Ley et al., 2007). 
 
1.4.2.3 Inflammatory mediators and endothelial cell activation  
During acute and chronic inflammation several classes of secreted mediators affect activation 
of macro- and microvasculature. The mediators of acute inflammation include vasoactive 
amines, plasma protein systems, prostaglandins and leukotrienes, acetyl glycerol ether 
phosphocholine, cytokines and nitric oxide (Rankin, 2004). These inflammatory mediators 
activate endothelial cells and attract leukocytes. Monocytes attracted to the site of local 
inflammation differentiate into macrophages under the influence of local pro-inflammatory 
factors and release a broad spectrum of biologically active substances. These include 
enzymes, chemokines, reactive oxygen species, cytokines and structural components of 
extracellular matrix (Duffield, 2003; Embleton, 2003; Zeremski et al., 2007). During chronic 
inflammation, macrophages secrete cytokines such as TNF-alpha, IL1, IL6, IL8 and IL12, 
chemokines, leukotrienes, prostaglandins, and complement components that induce increased 
vascular permeability and further attraction of inflammatory cells (Arango Duque and 
Descoteaux, 2014). During inflammation, angiogenesis is initiated by pro-angiogenic factors 
such as VEGF, PDGF and FGF released by macrophages and other cell types (Granger and 
Senchenkova, 2010). These pro-angiogenic factors allow endothelial cells to migrate and 
proliferate to form a cord-like structure in tissues which later can develop into functional 
vessels. Angiogenesis is a critical process for cancer progression, cardiovascular diseases and 
diabetic retinopathy (Granger and Senchenkova, 2010).  
 
1.5 Role of macrophages in the regulation of metabolic conditions 
Recent evidence at the cellular and molecular level proved that obesity can be a chronic low-
grade inflammatory disease, where macrophages play a role in the regulation of glucose and 
lipid metabolism (Vandanmagsar et al., 2011b; Weisberg et al., 2003). In lean conditions, 
adipocytes release factors such as IL13, promoting alternative activation of macrophages 
(Olefsky and Glass, 2010).  
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Activated alternatively activated macrophages (M2) secrete anti-inflammatory cytokines, such 
as IL10, and lead to the release of insulin-sensitising factors (Figure 6) (Olefsky and Glass, 
2010). In obese conditions, monocytes are actively recruited to the adipose tissue by 
adipokines, including CCL2, and differentiate into adipose tissue macrophages (ATM). 
During obese conditions, several factors effect the change of adipocyte metabolism and 
expression of genes leading to enhanced lipolysis and production of free fatty acids and 
factors (CCL2, TNF-alpha), attracting monocytes and driving the M1-type of macrophage 
activation (Figure 6) (Olefsky and Glass, 2010; Ray et al., 2016). These activated M1 
macrophages secret several pro-inflammatory mediators, such as IL-1beta, TNF-alpha, IL6, 
leukotriene B4, nitric oxide and resistin, which induce insulin resistance in adipocytes (Figure 
6) (Henao-Mejia et al., 2014; Hotamisligil et al., 1996; Olefsky and Glass, 2010). 
 
 
Figure 6.  Factors affecting macrophage polarity and insulin resistance in adipose tissue. 
Permission obtained from Copyright Clearance Center (Olefsky and Glass, 2010). 
 
Similar mechanisms are involved in inflammation-dependent insulin resistance in other cells, 
including pancreatic beta cells (Emanuelli et al., 2004). In obesity, inflammatory and 
metabolic stress conditions are created, not only in fat tissue, but also in other organs,  
including pancreatic islets, the liver and muscle, that leads to increased local production of 
cytokines and chemokines such as IL-1beta, TNF-alpha, CCL2, CCL3 and CXCL8/IL8 
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(Figure 7) (Ray et al., 2016). These cytokines mediate the recruitment of immune cells in 
insulin-sensitive tissues, amplifying inflammatory reactions that in turn interfere with insulin 
signalling by activation of NF-kB and JNK-mediated pathways and augment transcription of 
genes involved in lipid processing (Ray et al., 2016). 
 
 
Figure 7. Schematic presentation of obesity-induced inflammation in the peripheral organs. 
During obesity, inflammatory reactions are mediated by tissue-specific macrophages in adipose tissue, 
the liver, skeletal muscle and the pancreas. During obesity, tissue-specific macrophages change their 
phenotype from M2 (alternatively activated macrophages) to M1 (classically activated 
macrophages).  Obesity-induced inflammation leads to the development of dysbiosis in the intestine. 
AC (adipocyte); KC (Kupffer cell); L (lipid droplets); AT (adipose tissue); NK (natural killer cell); 
PMN (polymorphonuclear neutrophil); WAT (white adipose tissue). Reprinted from distributed under 
the Creative Commons Attribution-Non-Commercial License (Ray et al., 2016).    
 
1.6 Effect of hyperglycaemia on monocytes and macrophages 
Despite recognising the critical role of macrophages in the regulation of metabolic processes 
and vascular compilations in diabetes, information about the direct effect of hyperglycaemia 
on the activation of human primary macrophages is still limited. M1 macrophages utilise the 
glycolytic pathway for the generation of energy, while M2  macrophages utilise fatty acids as 
an energy source, whereas PPAR δ and PPAR γ transcription factors, as well as  co-activator 
PGC1β, are important for the stimulation mitochondrial biogenesis and fatty acid β-oxidation 
(Johnson et al., 2012; Tannahill et al., 2013; Vats et al., 2006).  Experimental animal models 
and as well as in vitro models provided evidence demonstrating the effect of hyperglycaemia 
on the biology of monocytes and macrophages. The stimulating effect of hyperglycaemia on 
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the leukocytosis resulting in an increased amount of circulating monocytes (predominantly 
the Ly6-C
hi
 pro-inflammatory subset) and neutrophils, was demonstrated in mouse models of 
insulin-deficient diabetes (Nagareddy et al., 2013). 
 
High-fat diet (HFD)-induced obesity leads to an accumulation of adipose tissue macrophages 
(ATMs), critical for the pathogenesis of T2D (Fujisaka et al., 2009). In a STZ-induced 
diabetic mice model it was found that hyperglycaemia induces the appearance of proinsulin 
(PI)-producing pro-inflammatory bone marrow (BM)-derived cells (PI-BMDCs) (Kojima et 
al., 2004). Furthermore, using a high-fat diet (HFD)-induced obesity mouse model, it was 
found that amelioration of hyperglycaemia by different hypoglycaemic agents prevented 
accumulation of  PI-producing ATMs as well as adipose inflammation, the critical factors for 
the development of systemic insulin resistance (Buras et al., 2015).  
 
The direct effect of hyperglycaemia on the production of increased amounts of TNF-alpha, 
IL-1beta and CCL2 was also identified using the human monocytic cell line THP-1 as a 
model, where the central role of NF-kB in response to THP-1 cells in hyperglycemic 
conditions was demonstrated (Dasu et al., 2007; Guha et al., 2000; Shanmugam et al., 2003a). 
In addition to activation of inflammatory cytokine release, a stimulating effect of 
hyperglycaemia adhesion of THP-1 cells to HUVEC monolayer was also shown; 
transmigration and stress fiber response was demonstrated (Nandy et al., 2011). These effects 
correlated with activation of the Akt, and glycogen synthase kinase (GSK3β) and PI-3 kinase 
pathways  (Nandy et al., 2011).  Hyperglycaemia was found to enhance the response of THP-
1 cells to LPS. Thus, cultivation of THP-1 cells for 24 hours in the presence of high (25mM) 
versus normal (5.5mM) glucose concentrations led to a significant increase of LPS-induced 
release of TNF-alpha and CCL2 (Iwata et al., 2007). The effect of hyperglycaemia on 
cytokine release was also analysed in vitro using human primary PBMC-derived macrophages 
(Lachmandas et al., 2015). It was found that stimulation of M0 and M2 macrophages on day 6 
with LPS and M. Tuberculosis lysate (H37Rv) slightly increased the release of both pro-
inflammatory (TNF-alpha, IL6) and anti-inflammatory cytokines (IL10, IL-1Ra). However, 
the strongest effect was found upon the release of IL10 in M0, while effects of 
hyperglycaemia on the inducible production of TNF-alpha and IL6 were not more than 30%. 
The biological significance of the LPS and M. Tuberculosis – induced production of TNF-
alpha and IL6 in hyperglycaemic conditions was questionable and was not associated with an 
increase in bacterial killing of phagocytic activity of macrophages. The limited biological 
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significance of the data obtained in this experiential system was also related to the 
differentiation of primary macrophages in RPMI medium, but not in macrophage-specific 
serum free medium (Lachmandas et al., 2015). Therefore, the information about the 
mechanisms of hyperglycaemia-mediated activation of macrophages is mostly limited to the 
data obtained in mouse models and in human THP-1 cells, which significantly differ in their 
biological activities from primary human macrophages. The current interpretation of the 
increased responsivity of macrophages to bacterial inflammatory stimuli is that 
hyperglycaemia can “prime” macrophages to inflammatory reactions (van Diepen et al., 
2016). 
 
1.7 Epigenetic mechanisms 
Epigenetic mechanisms are responsible for the meiotically or mitotically heritable changes 
that regulate gene expression independent of changes in nucleotide sequence (Allis and 
Jenuwein, 2016; Egger et al., 2004). Epigenetic changes can be constitutive and cell-type 
specific or can be induced by several factors such as age, environment, lifestyle and disease 
state. These epigenetic modifications are reversible by modulation of environmental, dietary 
or pharmacological interventions (Allis and Jenuwein, 2016; Egger et al., 2004). There are 
three major epigenetic mechanisms that regulate gene expression: DNA methylation, histone 
modifications and non-coding RNAs (ncRNAs) (Allis and Jenuwein, 2016; Collins et al., 
2011; Egger et al., 2004).   
1.7.1 DNA methylation 
DNA methylation is the first epigenetic mechanism that was identified. DNA methylation is 
an addition of methyl groups to the cytosine residue by enzymes named DNA 
methyltransferases (Du et al., 2015). DNA methylation most frequently occurs at CpG islands, 
which are associated with the promoter regions of genes (Deaton and Bird, 2011). DNA 
methylation results in the suppression of transcription (Dantas Machado et al., 2015; Riggs, 
1975). DNA methylation is a critical component in many cellular processes, including 
embryonic development, genomic imprinting, X-chromosome inactivation and preservation 
of chromosomal stability (Horvath, 2013; Phillips, 2008).  In cancer, DNA methylation is 
well characterised. In transformed cells, tumour suppressor genes can be downregulated by 
hypermethylation, while hypomethylation promotes activation of proto-oncogenes (Klutstein 
et al., 2016; Phillips, 2008).  The process of DNA methylation occurs in dividing cells and is 
an essential mechanism that controls cell differentiation. DNA demethylation can be a passive 
of active process, where passive demethylation is a consequence of the absence of active 
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methylation during DNA replication in dividing cells. In contrast, active removal of methyl 
groups can be independent of DNA replication and can occur in non-dividing cells.  
1.7.2 Histone modifications 
Histones are major structural proteins of chromatin that interact with DNA and define 
chromatin structure. There are five major histones: H1, H2a, H2b, H3 and H4 (Bhasin et al., 
2006).  H2a, H2b, H3 and H4 are referred to as “core histones”, while histone H1 is referred 
to as linker histone. The core histones form dimers, and these four distinct dimers come 
together to form one octameric nucleosome core. Histones are subjected to post-translational 
modifications including, among others, methylation, acetylation, phosphorylation, 
SUMOylation, ubiquitination, biotinylation, citrullination, ADP-ribosylation and cis-trans 
isomerization (Figure 8) (Egger et al., 2004; Latham and Dent, 2007).  The histone code 
concept defines which post-translational modifications of histones alone or in combination 
modulate chromatin structure and function (Prakash and Fournier, 2016). Activated histone 
modifications are associated with the formation of transcriptionally active euchromatin. 
Repressing histone modifications leads to the formation of transcriptionally inactive 
heterochromatin. Major histone modifications that are involved in the regulation of gene 
expression include acetylation and methylation (Egger et al., 2004; Latham and Dent, 2007). 
Acetylation of histones at any amino acid and any position acts as an activating mechanism 
for transcription. Histone methylation can act both as an activating and repressing mechanism 
depending on the type and position of amino acid, and the amount of methyl groups added. 
For example, addition of single, double or triple  methyl groups to the lysine (K4) on a 
histone 3 (H3) acts as an activating histone code, while the addition of single, double or triple 
methyl groups to lysine 9 (K9) on histone 3 (H3) acts as a repressing histone code 
(H3K9me3). However, mono-methylation of lysine 27 (K27) on histone 3 (H3) is an 
activating histone mark (H3K27me1), and tri-methylation of lysine 27 (K27) on histone 3 
(H3) is a repressing histone mark (H3K27me3) (Barski et al., 2007; Egger et al., 2004).  
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Figure 8. Post-translational modifications of histones. (A)  Types of post-translational 
modifications at the amino acid residues (B) Amino acid residues that can undergo different forms of 
post-translational modification or can cross-talk. Each modification inhibits subsequent modification. 
Numbers indicate the position of amino acid.  Permission obtained from Copyright Nature Publishing 
Group (Latham and Dent, 2007).  
 
Patterns of histone modifications correlate with the dynamics of chromatin (Peterson and 
Laniel). Histone modifications control structure and chromatin fibres, where site-specific 
combinations define particular biological functions. Each type of histone modification is 
catalysed by a specific class of enzymes (histone acetyltransferases/HATs, histone 
methyltransferases/HMTs). These modifications are reversible and can be removed by histone 
deacetylases/HDATs and histone demethylases/HDMs correspondingly (Figure 9) 
(Arrowsmith et al., 2012). The histone code is a highly flexible system and provides the 
possibility of the cell to respond to a range of extracellular stimuli, including inflammatory 
and metabolic stimuli, without the event of cell division. Therefore, the histone code is the 
major epigenetic mechanism that controls activation of phenotypically and functionally 
plastic cells--macrophages (Ahmed et al., 2016). The histone code can act in cooperation with 
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DNA methylation to define the chromatic structure. Moreover, histone modification can be 
recognised by a number of proteins that control transcription of specific genes (“readers” of 
the histone code).  
 
Figure 9. Epigenetic regulation of gene expression by histone modifications. Permission obtained 
from Copyright Nature Publishing Group (Arrowsmith et al., 2012). 
 
1.7.3 Non-coding RNA 
A non-coding RNA is a functional RNA molecule that is transcribed from DNA but is not 
translated into a protein (Collins et al., 2011). Epigenetically related classes of ncRNAs 
include 1) long ncRNAs, and 2) short ncRNAs including miRNA and siRNA (Collins et al., 
2011; Kurokawa et al., 2009).  All these ncRNAs are also called RNAi. The short and long 
ncRNAs are involved in chromatin-mediated gene silencing and DNA rearrangements 
(Collins and Penny, 2009; Gangaraju and Lin, 2009). A study by Wang et al. demonstrated 
that maize organ-specific distributions of canonical miRNAs and endogenous siRNAs have 
been linked to epigenetic modifications on the level of DNA methylation and the histone code 
(Wang et al., 2009). It was demonstrated that long ncRNAs and miRNAs are involved in 
diabetic complications (Beltrami et al., 2015; Prattichizzo et al., 2015a; Reddy et al., 2015). 
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1.8 Epigenetic control of macrophage activation 
All three epigenetic mechanisms contribute to the development of differentiated macrophage 
phenotypes. Whole-genome bisulfite sequencing revealed that human primary monocytes 
undergo significant DNA demethylation during their differentiation into macrophages 
(Wallner et al., 2016). 114 DMRs (differentially methylated regions) that have a methylation 
difference equal or greater than 0.3 were identified, where 110 out of 114 were demethylated 
during monocyte-macrophage differentiation.  This study demonstrated that DNA 
demethylation is a critical process for the differentiation of monocytes to macrophages, 
providing conditions for the next level of regulation of chromatin structure and function by 
the modification of the histone code (Wallner et al., 2016). In macrophages, M1 and M2 
activation and differentiation states were demonstrated to depend significantly on post-
translational modifications of histones (Kapellos and Iqbal, 2016b; Saeed et al., 2014). 
Histone modifications such as methylation, acetylation, demethylation and deacetylation 
influence the development of macrophage phenotypes (Medzhitov and Horng, 2009; Saeed et 
al., 2014; Takeuch and Akira, 2011). It was demonstrated that IL4 stimulated bone marrow 
derived macrophages induce the STAT6-dependent jmjd3 protein, which leads to a decrease 
in H3K27me2/3 levels and increases the H3K4me3 levels on M2 macrophage markers’ 
promoter regions (Ishii et al., 2009; Takeuch and Akira, 2011). ChIP-qPCR demonstrated 
changes of histone marks on M2 markers (chi3I3, retnla and Arg 1) (Ishii et al., 2009). This 
study also demonstrated that a decrease in H3K27 methylation is associated with increased 
recruitment of Jmjd3 in M2 macrophages (Ishii et al., 2009). Epigenetic changes during 
differentiation of human monocytes into naïve macrophages (without stimulation), trained 
immunity macrophages (stimulated with beta-glucan) and innate immune macrophages 
(stimulated with LPS) were found at promoter sites (Saeed et al., 2014). A dynamic change 
for the association of activating histone marks H3K4me1, H3K4me3 and H3K27ac with 
chromatin was demonstrated during monocyte to macrophage differentiation in all three 
settings (Saeed et al., 2014). It was also shown that H3K27 acetylation was decreased on 1240 
promoters and increased on  1307 other promoters, further supporting the importance of 
histone modifications in the regulation of gene expression during macrophage differentiation 
(Saeed et al., 2014).  It was also demonstrated that a miRNA signature was responsible for the 
polarisation of human monocyte-derived macrophages under stimulation with IFNg + TNF-
alpha (M1), IL4 (M2a) and IL10 (M2c) (Cobos Jimenez et al., 2014).  
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1.9 Epigenetics in diabetes  
Epigenetic mechanisms are involved in the development of diabetic complications and can be 
a major mechanism underlying the phenomenon of metabolic memory (Prattichizzo et al., 
2015a; Reddy et al., 2015). Lifestyle factors such as nutrition, the level of physical activity 
and cigarette smoking can induce T2D by influencing epigenetic factors (Reddy et al., 2015). 
Diabetes and metabolic factors can induce several growth factors and lipids that can 
stimulate multiple signalling pathways, transcription factors (TFs) and crosstalk with 
epigenetic networks (Prattichizzo et al., 2015a; Reddy et al., 2015). These events can change 
the structure of chromatin and regulate the pathological genes relevant to diabetic 
complications. Persistence of such epigenetic aberrations, including a change in DNA 
methylation, histone code and ncRNA profiles, may lead to metabolic memory, which 
results in an increased risk of developing diabetic complications even after normalisation of 
hyperglycaemia (Reddy et al., 2015).  
 
Diabetes and diabetogenic agents such as high glucose, AGEs, Ang II, TGF-beta and oxidized 
lipids have detrimental effects on several cell types involved in vascular dysfunction, such as 
endothelial cells, vascular smooth muscle cells and renal cells (Figure 10) (Beckman et al., 
2002; Natarajan and Nadler, 2004; Reddy et al., 2015). These diabetogenic agents activate 
several signalling pathways that lead to the activation of transcriptional factors, such as NF-
kB and SMADs. Activation of NF-kB and SMADs results in the production of growth factors, 
inflammatory chemokines and cytokines involved in dysfunction of endothelial cells and 
inflammation, that lead to the progression of vascular complications (Figure 10) (Reddy et al., 
2015). Although hyperglycaemia can be controlled by medications, exercise and dietary 
modifications, many patients still continue to experience numerous vascular complications 
(Reddy et al., 2015).  This could be due to so-called “metabolic memory” of prior exposure of 
target cells to hyperglycaemia, where epigenetic mechanisms play an essential role (Figure 
10) (Reddy et al., 2015).  
 
Diabetes–associated epigenetic mechanisms were mostly studied in endothelial cells. It was 
demonstrated that in primary human aortic endothelial cells that transient hyperglycaemia 
causes persistent atherogenic effects by inducing long-lasting changes in chromatin 
remodelling through the recruitment of the histone methyltransferase SET7. Recruitment of 
SET7 is associated with increased H3K4 monomethylation at the NF-κB promoter leading to 
increased expression of p65, MCP-1 and VCAM-1 (El-Osta et al., 2008). Brasacchio et al. 
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have demonstrated that transient hyperglycaemia induced the enrichment of SET7 
(responsible for monomethylation of H3K4) on the NFkappaB-p65 promoter in bovine aortic 
endothelial cells; knockdown of SET7 attenuated glucose-induced activation of the p65 gene 
(Brasacchio et al., 2009). Transient hyperglycaemia stimulated lysine-specific demethylase 1 
(LSD1) resulting in reduced H3K9 methylation and increased NFκB-p65 expression 
(Brasacchio et al., 2009). However, whether the same epigenetic mechanisms that were 
identified in the endothelial cells are induced by hyperglycaemia in other cell types, including 
macrophages, remain to be identified.  
 
Figure 10. Signalling and epigenetic networks mediating the pathogenesis of diabetic 
complications and metabolic memory. AT1R (Ang II type 1 receptor); MI (myocardial infarction); 
oxLDL (Oxidized-LDL); RAGE (Receptor for AGEs); SR (scavenger receptors); TBR (TGF-β 
receptor). Permission obtained from copyright Springer (Reddy et al., 2015).  
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1.10 The aims and objectives of the project 
The major goal of the current study was to analyse the effect of hyperglycaemia on the 
programming of primary human macrophages related to the development of diabetes and its 
vascular complications. Despite recognising the critical role of inflammation in the 
progression of diabetes and the development of diabetic vascular complications, the direct 
effect of hyperglycaemia on the epigenetic programming of pro-inflammatory activities of 
human primary macrophages remained to be identified. In this study, for the first time, we 
established a model system for the analysis of primary human monocyte to macrophage 
differentiation in normal and hyperglycaemic conditions that enabled the analysis of the effect 
of hyperglycaemia on the activation and epigenetic programming of macrophages.  
 
The specific aims of the present study were: 
1. Identification of hyperglycaemia-induced changes in gene expression and secretion of 
major M1 and M2 marker cytokines in human primary M0, M1 and M2 macrophages.  
 
2. Identification of the complete program of transcriptional changes induced by 
hyperglycaemia in human primary M0, M1 and M2 by Affymetrix DNA microarray.  
 
3. To analyse functional changes in macrophages under hyperglycaemic conditions 
 
4. To analyse the role of the histone code in the regulation of hyperglycaemia-induced 
gene expression by chromatin immunoprecipitation assays (ChIP). 
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2. Materials and Methods 
This work was written with the operating system Windows 10 and the text processing program 
Microsoft Office Word 2010. The presented pictures, as well as numerous reports, have been 
processed using the programs Microsoft Office Excel 2010, GraphPad Prism 5, ImageJ, Corel 
Draw Graphics Suite 12 and Photoshop CS6 
2.1  Chemicals, reagents and kits 
Product Company 
0.05% Trypsin/EDTA solution Biochrom AG 
10x Incomplete PCR buffer BIORON 
30% Acrylamide/Bis Solution, 37.5:1 Bio-rad 
4′.6-diamidino-2-phenylindole (DAPI) Roche 
50x Tris-Acetate EDTA (TAE) buffer Eppendorf 
Agarose Roth 
Amersham Hyperfilm ECL GE Healthcare 
Ammonium persulfate (APS) Merck Millipore 
Bovine Serum Albumin (BSA)  Sigma 
Calf Intestinal Alkaline Phosphatase Thermo Scientific 
Complete, EDTA-free Protease Inhibitor Cocktail Tablets Roche 
Dako Fluorescent Mounting Medium Dako Cytomation 
Deoxyribonucleotides (dNTPs) 10M Fermentas 
DEPC Water Thermo Scientific 
Dimethylsulfoxide (DMSO) Sigma 
DMEM medium Life Technologies 
DNase Buffer(10x) Thermo Scientific 
DNase I lyophilized Roche 
DNase I RNase free 1U/µl solution Fermentas 
DRAQ5  Biostatus Ltd. 
Ethanol Roth 
Expand High Fidelity PCR Kit Roche 
Foetal calf serum (FCS) Biochrom AG 
Gel Code Blue stain reagent Pierce 
GeneRuler DNA ladder Fermentas 
Glycerol Sigma 
Hepes buffer Sigma 
Isopropanol Merck Millipore 
Isopropyl-β-D-thiogalactopyranosid (IPTG) Sigma 
Laemmli sample buffer Bio-Rad 
LB broth / agar (Lennox) Sigma 
Loading dye 6x Fermentas 
Methanol Merck Millipore 
MgCl2 Sigma 
MnCl2 1 M Sigma 
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Product Company 
Gel Red DNA Gel Stain Biotium 
Oligo(dt) primer Thermo Scientific 
Omnipure-OLS kit  Omnilife Science 
Page Ruler Plus Prestained Protein Ladder (10-250 kD) Fermentas 
Paraformaldehyde (PFA)  Fluke 
PBS Dulbecco, w/o Ca 
2+
, Mg 
2+
 Biochrom AG 
PCR primers Eurofins MWG Operon 
PCR probes Eurofins MWG Operon 
Phenylmethylsulfonyl fluoride (PMSF) Sigma 
Phosphate buffered saline (D-PBS), sterile 1x Invitrogen 
Polybrene Sigma 
Poly-D-Lysine Sigma 
Protein Assay Reagent Bio-Rad 
Protein G Sepharose Amersham Biosciences 
Sodium dodecyl sulphate (SDS) 10% Bio-Rad 
Sodium pyruvate (100mM) Sigma 
ß-Mercaptoethanol Sigma 
Subcloning Efficiency DH5α Competent Cells Life Technologies 
Taq polymerase 5 u/µl BIORON 
TEMED Genaxxon 
Triton X-100 Sigma 
Tween 20 Sigma 
 
2.2 Consumables 
Product Company 
22x22mm coverslips Marienfeld 
22µm filters Fisherbrand 
Cell culture plates Greiner 
Cryovials Nunc 
Glass slides Servoprax 
Parafilm American National Can 
PCR tubes Star Labs 
Petri dishes Star Labs 
Pipette tips Eppendorf 
Pipettes Gilson, Eppendorf 
Plastic wrap Topics 
Safe-Lock Eppendorf Tubes, 1.5ml Eppendorf 
Scalpel Feather 
Sterile Pipette tips Avantguard, Star Labs, Nerbeplus 
Tubes Falcon 
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2.3 Equipment 
Equipment used in the study 
Product Company 
Agarose electrophoresis unit i-Mupid Erogentec 
Autoclave VX-95 Systec 
BD FACSCanto II BD 
Cell counter Scharfe system 
Centrifuge 5415 D Eppendorf 
Centrifuge 6K15 Sigma 
Centrifuge RC 5C Plus Sorvall 
Cryo freezing container Nalgene 
Deep freezer (-80°C) Sanyo 
Electrophoresis comb Peqlab 
Electrophoresis power supply Peqlab 
Freezer (-20°C) Liebherr 
Glass plates Peqlab 
Glass syringe Hamilton 
Homogenizer Ultra Turrax T8 Ika-werke 
Ice machine Scotsman AF100 
Incubator 37°C Edmund Bühler GmbH 
Inverted microscope Leica 
Laminar flow hood Thermo 
Confocal software Leica 
TCS SP2 laser scanning spectral confocal microscope  Leica 
Magnetic stirrer.MR3000 Heidolph 
Microwave oven Sharp 
Neubauer haemocytometer Assistent 
Pipette Controller  Accu Jet Pro, Brand 
Roller Ortho Diagnostic Systems 
Rotator Neolab 
SDS-PAGE chamber Peqlab 
SDS-PAGE gel comb Peqlab 
SDS-PAGE power unit Power-Pac 200 Bio-Rad 
SDS-PAGE unit Biometra 
Shaker KS 260 basic IKA 
Sorvall RC5C Plus ultracentrifuge Thermo Scientific 
Staining Dish Neolab  
Staining rack Neolab 
Tecan Infinite 200 Tecan 
Thermocycler DNA Engine PTC220 Dyad MJ Research 
Thermomixer 5436 Eppendorf 
Thermomixer comfort Eppendorf 
Tweezers Neolab 
Ultracentrifuge tubes 50ml Thermo Scientific 
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Product Company 
UV fluorescent light Peqlab 
UV/Stratalinker 1800 Stratagene 
UV/Visible spectrophotometer Ultraspec 3000 Amersham 
Vortex Genie 2 Scientific Industries 
Water bath Memmert 
Water bath SW-21 Julabo 
Sonicator (Bioruptor) Diagenode 
 
2.4 Kits 
Following kits were used in the study 
E.Z.N.A. Total RNA Kit I Omega bio-tek 
QIAquick PCR Purification Kit  Qiagen 
RevertAid H Minus First Strand Synthesis Kit Fermentas 
RNAeasy mini kit   Qiagen 
 
2.5 Buffers and solutions 
Buffers used for chromatin immunoprecipitation are listed in the order of application 
ChIP buffer 50 mM HEPES-KOH pH7.5   
140 mM NaCl  
0.1% SDS  
1% Triton X-100 
 0.1% sodium deoxycholate 
1 mM EDTA pH8  
Protease inhibitors (Cat: 04693159001 Roche), freshly added to the buffer  
RIPA Buffer 50 mM Tris-HCl pH8  
150 mM NaCl  
0.1% SDS  
1% NP-40  
0.5% sodium deoxycholate 
2 mM EDTA pH8  
Protease inhibitors (Cat: 04693159001 Roche), freshly added to the buffer 
Low Salt  
Wash Buffer 
20 mM Tris-HCl pH 8.0  
150 mM NaCl 
0.1% SDS 
1% Triton X-100 
2 mM EDTA  
High Salt  
Wash Buffer 
20 mM Tris-HCl pH 8.0  
500 mM NaCl  
0.1% SDS  
1% Triton X-100  
2 mM EDTA  
LiCl  
Wash Buffer 
10 mM Tris-HCl pH 8.0 
0.25 M LiCl  
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1% NP-40  
1% sodium deoxycholate  
1 mM EDTA  
TE Buffer 10 mM Tris pH 8 
0 1 mM EDTA 
Elution Buffer 100 mM NaHCO3 
1% SDS  
 
2.6 Isolation of human CD14+ monocytes from buffy coats 
Buffy coats were provided by the German Red Cross Blood Service Baden-Württemberg – 
Hessen. Buffy coats were obtained from healthy blood donors after informed consent. For 
each buffy coat isolation (each donor) a unique number was given. The volume of buffy was 
usually 30 ml. Buffy coats were provided in protective bags. CD14+ monocytes were isolated 
out of buffy coats according to the following procedure, performed under sterile conditions. 
During the isolation procedure, on several steps, sterile PBS without Ca
2+
 and Mg
2+ 
was used 
(indicated as PBS in the protocol). 
1) First gradient: Biocoll gradient was prepared by addition of 15 ml of biocoll separating 
solution in a 50 ml falcon tube.  
2) Buffy coat package was cut, the contents were placed in a sterile T-75 flask and diluted 1:1 
with PBS. 
3) The diluted contents of the buffy coat was added to the 1st gradient falcon tube and 
centrifuged at 420 rcf for 30 min without breaks. 
4) First washing step: the upper layer (serum) was discarded and the second layer (enriched 
PBMC fraction) was collected in a fresh 50 ml falcon tube and filled up with PBS to 50 ml. 
Centrifugation was performed at 420 rcf for 10 min with breaks (first wash). 
5) Second washing step: the supernatant was discarded, and the cell pellet was resuspended in 
3 ml of PBS and filled up to 50 ml with PBS. Centrifugation was performed at 420 rcf for 10 
min. 
6) Third washing step and cell counting: supernatant was discarded, and the cell pellet was 
resuspended in 3 ml PBS and filled up to the 50 ml with PBS. Centrifugation was performed 
at 420 rcf for 10 min. 
7) An aliquot of 10 µl was taken for cell counting from the 50 ml suspension and mixed with 
10 ml of casytone solution. 
8) Second gradient: The Percoll gradient solution was prepared by mixing 13.5 ml Percoll, 15 
ml MEM medium and 1.5 ml 10x Earle´s salt solution per 30 ml sample and mixed well. 
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9) After the final wash, the cell pellet was resuspended in 4 ml PBS and the cell suspension 
was applied on the top of the percoll gradient very slow and carefully. The cells were 
centrifuged at 420 rcf for 30 min without breaks. 
10) The PBMC fraction (upper layer) was carefully collected and transferred to a 50 ml 
falcon tube and filled up to 50 ml with PBS and centrifuged at 420 rcf for 10 min with breaks. 
11) The supernatant was discarded, the cell pellet was thoroughly resuspended in 2 ml of 
PBS and transferred into a 15 ml falcon tube. PBS was added to obtain a volume of 10 ml; 
centrifugation was performed at 420 rcf for 10 min. 
12) The cell pellet was resuspended in 95 µl of MACS buffer (0.5% BSA, 2 mM EDTA 
dissolved in PBS) and 5 µl CD14 microbeads per 10
7
 cells (for the selection of CD14 positive 
monocytes). 
13) The cells were incubated for 15 min on a rotator at 4°C. The final volume was made up to 
10 ml with MACS buffer and centrifuged at 420 rcf for 10 min. The cell pellet was 
resuspended in 1000 µl of MACS buffer. 
14) An LS separation column was placed in the magnetic separation unit and washed with 3 
ml MACS buffer. A fresh collecting tube was placed, and the cell suspension (1000 µl) was 
applied onto the LS column. 
15) The column was washed 3 times with 3 ml MACS buffer. The LS column was removed 
from the magnetic separation unit and placed on a fresh 15 ml falcon tube. 
16) The CD14+ monocytes were eluted from the column with 5 ml MACS buffer in a 15 ml 
falcon tube. The cells were sedimented by centrifugation at 420 rcf for 10 min. 
17) The cell pellet was resuspended in SFM (serum-free medium) medium at a concentration 
of 1x10
6
 cells/ml. Cells were seeded in cell culture dishes and stimulated with different 
factors: IFNg at 100 ng/ml, IL4 at 10 ng/ml and M-CSF at 5 ng/ml were used as indicated in 
each specific experimental setup in the section results. 
 
2.6.1 Culturing primary human macrophages 
Glucose-free SFM medium was custom-made and purchased from Life Technologies. 
Glucose stock was added to the medium until a final concentration of 5mM and 25mM. 
Glucose concentration was controlled by an Accu-Chek glucose monitor.  
1) Isolated cells were cultured in SFM normal glucose medium (5mM) or high glucose 
medium (25mM) with 5 ng/ml of M-CSF. 
2) Cells were suspended at 1x106 cells per ml of medium. 
3) Cells were plated in 10cm dishes (10-15ml). 
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4) Cells were plated and stimulated with specific stimulations to differentiate into specific 
subtypes of macrophages [non-stimulation (M0), IFNg (M1) and IL4 (M2)] in normal and 
high glucose for 6 days. 
 
2.6.2 Collecting supernatants 
1) Supernatants were harvested on day 1, day 3 and day 6.  
2) These supernatants were frozen in a -80°C freezer until analysis by ELISA. 
 
2.7 RNA-related methods 
2.7.1 Isolation of total RNA  
For RNA Isolation, the E.Z.N.A. Total RNA Kit I was used.  
The lysis buffer was prepared by addition of 10 µl of -mercaptoethanol to 1 ml of the TRK 
buffer (guanidine isothiocyanate containing buffer which suppresses RNase activity) and 
mixed well.  
1) Cells (3-5X106 cells) were harvested and lysed in 350 µl of lysis buffer. Cells were 
completely disrupted by passing the lysate 10-15 times through a needle fitted with a syringe. 
An equal volume of 70% ethanol was added to the lysate. Each sample was vortexed and 
applied to a HiBind RNA spin column placed into a 2 ml collection tube.  
2) The column was centrifuged at 10,000 g for 1 min. After centrifugation, the flow-through 
was discarded, and the column was washed once with 500 µl of RNA wash buffer I and two 
times with 500 µl of RNA wash buffer II.  
3) After the last centrifugation, the column was placed in a fresh RNase-free microcentrifuge 
tube. The RNA was eluted 2 times with 50 µl of RNase-free water preheated at 70°C.  
4) The concentration of isolated RNA was determined with a Tecan Infinite 200. The quality 
of the obtained RNA samples was analysed on a 1.5% agarose gel. Isolated samples were 
stored at -20°C until use. 
 
2.7.2  RNA preparation for Affymetrix GeneChip analysis 
Total RNA was prepared using the E.Z.N.A. Total RNA Kit I as described above.  
1) The volume of RNA sample was adjusted to 100 µl.  
2) 12 µl of 10X DNAase I buffer with MgCl2 (Fermentas) and 10 µl of RNAse free DNAse I 
(Fermentas) were added to the sample and mixed well by pipetting.  
3) DNA digestion was done at 37°C for 40 min in a thermal block followed by a clean-up 
procedure with the Rneasy kit from Qiagen.  
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4) 350 µl of RLT buffer was added to the sample and mixed well. 250 µl of 100% ethanol 
was added to the sample and mixed by pipetting.  
5) The sample was applied to an RNeasy mini column and centrifuged at 10,000 g for 1 min. 
After centrifugation, the flow-through was discarded, and the column was washed two times 
with 500 µl of buffer RPE.  
6) After the last centrifugation, the column was placed in a fresh RNase-free microcentrifuge 
tube. The RNA was eluted 2 times with 50 µl of RNase-free water preheated at 70°C.  
7) The concentration of the RNA was measured by using a Tecan Infinite 200 
8) The quality of RNA was examined by gel electrophoresis. 
9) An aliquot of RNA was used for cDNA synthesis for RT-PCR or store separately from the 
total amount of RNA to avoid repetitive freeze/thaw cycles. 
10) The rest of the isolated RNA was stored at -80oC. 
 
2.7.3  Hybridization and statistical analysis of gene chip microarray 
Total RNA samples were provided to the core facility of the Medical Research Centre of the 
Medical Faculty Mannheim, University of Heidelberg. A final confirmation of RNA quality 
was performed using an Agilent 2100 Bioanalyzer by Ms. Carolina de la Torre in the core 
facility of the Medical Research Centre of the Medical Faculty Mannheim, University of 
Heidelberg. Next, synthesis of cDNA and hybridization was performed. For the hybridization, 
Human gene 1.0 from Affymetrix (cat N 901086) was used. Scanning of chips were 
performed by the technical assistant Ms. Carolina de la Torre in the core facility of the 
Medical Research Centre of the Medical Faculty Mannheim, University of Heidelberg. 
Statistical analysis was done by Dr. Carsten Sticht in the core facility of the Medical Research 
Centre of the Medical Faculty Mannheim. 
 
2.7.4 First strand cDNA synthesis for RT-PCR 
All RNA samples were digested with DNase I to remove genomic DNA contamination. 
The following reaction set-up was used: 
Total RNA 5 µl (1 µg) 
10X DNAseI buffer with MgCl2 (Fermentas) 1 µl 
RNAse free DNAse I (Fermentas)  1 µl 
Distilled water (RNAse free)  3 µl 
Digestion was done at 37°C for 40 min and followed by inactivation of the enzyme at 70°C 
for 10 min. 
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For the cDNA synthesis, the RevertAid H Minus First Strand Synthesis Kit (Fermentas) was 
used. After DNAse I digestion, cDNA was synthesised according to the following protocol:  
1) 1 µl of Oligo dT primer was added to the above RNA sample. 
2) The volume was adjusted with ddH2O up to 12 µl and annealing of the primer was done at 
70°C for 5 min. 
3) The samples were placed on ice for 1 min. 
4) The following reagents were then added: 
5X buffer for polymerase 4 µl 
Ribolock RNAse inhibitor   1 µl 
10 mM dNTP mix  2 µl 
RevertAid H minus reverse transcriptase                             1 µl
 
5) The reaction was incubated at 42°C for 1 h and activity of the enzyme was stopped by an 
additional incubation at 70°C for 10 min.  
6) The cDNA sample was diluted 10 times with ddH2O. 
7) The PCR reaction and agarose gel electrophoresis with 2% agarose gel were done as 
described above.  
 
2.7.5 Real-time PCR with Taqman probe 
All primers and dual-labelled probes were obtained from Eurofins ( 
Germany). Dual-labelled probes contained FAM on the 5’ end and a BHQ1 quencher at the 3’ 
end of the sequence. A list of used primers is shown in Table 10. All primer sequences are 
shown from the 5’ end to 3’ end direction. 
 
2.7.6 Optimisation of primers for qRT-PCR 
1) A primer optimisation assay was done for each gene to obtain the optimal probe and 
primer concentration to generate the lowest Ct value. 
2) A combination of three concentrations (50nM, 300nM and 900 nM) of both forward and 
reverse primers with a constant probe concentration (250nM) was used. 
3) The combination showing the lowest Ct value for forward and reverse primers was fixed, 
and TaqMan probe optimisation was optimised with five different TaqMan probe 
concentrations (50nM, 100nM, 150nM, 200nM and 250nM). 
4) The combination of primer and TaqMan probe concentration that yielded optimal assay 
performance was chosen for further experiments.  
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Table 1. List of primers used for Real-Time PCR. Primer concentrations were optimised 
according to section 2.7.6. Primers for coding sequence (cs) or promoter region (promoter) 
were used in the study  
Name of 
gene  
Primer 
names 
Primer sequence Primer 
concentr
ation 
Human 
GAPDH 
Cs 
FP848 TCCATGACAACTTTGGTATCGT 18 µM 
RP848 CAGTCTTCTGGGTGGCAGTGA 6 µM 
Pr849 AAGGACTCATGACCACAGTCCATGCC 4 µM 
CCL18 cs 
FP2020 ATACCTCCTGGCAGATTCCAC 18 µM 
RP2020 GCTGATGTATTTCTGGACCCAC 6 µM 
Pr2020 CAAGCCAGGTGTCATCCTCCTAACCAAGAGAG 4 µM 
TNF-alpha 
Cs 
FP896 TCTTCTCGAACCCCGAGTGA 18 µM 
RP896 AGCTGCCCCTCAGCTTGA 18 µM 
Pr896 AAGCCTGTAGCCCATGTTGTAGCAAACC 5 µM 
IL-1beta 
Cs 
FP2150 ACAGATGAAGTGCTCCTTCCA 18 µM 
RP2150 GTCGGAGATTCGTAGCTGGAT 18 µM 
Pr2150 CTCTGCCCTCTGGATGGCGG 5 µM 
IL-1Ra 
Cs 
FP2145 GAAGATGTGCCTGTCCTGTGT 18 µM 
RP2145 CGCTCAGGTCAGTGATGTTAA 18 µM 
Pr2145 TGGTGATGAGACCAGACTCCAGCTG 5 µM 
CCR2 
Cs 
FP2241 GACCAGGAAAGAATGTGAAAGTGA 18 µM 
RP2241 GCTCTGCCAATTGACTTTCCT 18 µM 
Pr2241 CACAAGGACTCCTCGATGGTCGTGG  4 µM 
 
18srRNA 
FP2242 CCATTCGAACGTCTGCCCTAT 6 µM 
RP2242 TCACCCGTGGTCACCATG 18 µM 
Pr2242 ACTTTCGATGGTAGTCGCCGTGCCT 5 µM 
CCR2 
promotor 
FP2244 GCACAACGATTGTCAGGAAA 18 µM 
RP2244 TTGGTGGAAGCTTCTTAGGG 18 µM 
Pr2244 CGTCACCCTACTTGGAGCAGAGCA 5 µM 
IL-1beta 
promotor 
FP2245 AAAGACTCCAAGCCCACAAT 18 µM 
RP2245 CCTAACCTCTAGCCCAGCAG 18 µM 
Pr2245 TCCCTCTCCCTCCAAGCCACA 5 µM 
 
A TaqMan primer mix for each gene was prepared according to the concentration in Table 1. 
For analysis of gene expression, a real-time PCR reaction was set up with the following 
components (for single reaction): 
TaqMan Gene Expression Master Mix 5 µl 
TaqMan primer mix (target) 0.5 µl 
TaqMan primer mix (reference) 0.5 µl 
cDNA 1 µl 
Distilled water   3 µl 
Usually, master mix without cDNA was prepared for the planned amount of reactions (20-
90). Each cDNA sample was analysed in triplicates. For normalisation, the expression of 
18srRNA mRNA was used for each reaction. Amplification
 
was performed using a 
LightCycler 480 instrument. The following program was used: 
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1 cycle 95°C 3 min 
50 cycles 
95°C 10 sec 
60°C 30 sec 
 
2.8 Protein techniques 
2.8.1 ELISA 
ELISA was used to identify concentrations of secreted factors in macrophage conditioned 
supernatants (described as “samples” in the protocols). Sample preparation is described in 
Table 4. All procedures were performed at RT. 
1) A 96 well Plate was coated with capture antibody provided in the kit for overnight 
incubation.  
2) The next day these plates were washed with wash buffer (PBS with 0.01% Tween 20) and 
incubated with 1% BSA/PBS for 1 hour for blocking.  
3) After blocking, the 96 well plate was washed 3 times; 50µl of 1% BSA/PBS and 50µl of 
the sample was added to each well.  
4) The standard was added according to the manufacturer’s instructions and incubated for 2 
hours. 
5) After incubation, the plate was washed 3 times with wash buffer.  
6) 100µl of detection antibody was added according to the manufacturer’s instructions and 
incubated for 2 hours 
7) 100µl of human-specific cytokine conjugated was added to each well and incubated for 20 
min. 
8) The substrate solution was added to each well and incubated for 20min. 
9) Stop solution was added to stop the reaction. 
10) The change of colour was measured in a Tecan Infinite 200 with the wavelength set 
according to the manufacturer’s instructions. 
Table 2. Sample preparation of ELISA. Macrophage supernatants were used in the non-diluted or 
diluted form to fit in a standard curve of ELISA. The optimal dilution was identified for each cytokine 
and each individual donor-derived macrophage culture. 
Secreted cytokine 
analysed by ELISA 
Macrophage 
stimulation  
Dilution of supernatant 
TNF-alpha NS, IFNg, IL4  Non-diluted, all days analysed 
IL-1beta NS, IFNg, IL4  Non-diluted, all days analysed 
IL-1Ra IL4 Dilutions: 1:10 or 1:50, day 6  
CCL18 IL4 
 
Dilutions: 1:10 or 1:50, day 3 
Dilutions 1:500, 1:1000 or 1:5000, day 
6  
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2.9 Cell migration assay 
1) For performing of the migration assay, the transwell inserts with 5µm pore membrane 
filters (BD Biosciences, San Jose, CA) were used.  
2) Primary human monocyte-derived macrophages were placed on ice for 30 min to detach 
the cells and these cells were harvested for migration assays.  
3) These cells were counted with the CASYton cell counter and 1*105cells/100µl/well were 
loaded onto the upper chamber. CCL2 was used as a chemoattractant at a concentration of 
100ng/ml (600 µl/well into the lower well compartment).  
4) After overnight incubation at 37°C, the upper sides of the filters were carefully washed 
with cold PBS, and the remaining non-migrated cells were removed with a cotton swab.  
5)  The cells were fixed with ice-cold methanol (800µl /well) and incubated at -20°c for 5 
min.  
6) Methanol was removed and washed with ddH2O 3 times for 10 min each at RT on a 
shaker.  
7) The cells were stained with DAPI. The insert was removed, and the filter was cut with the 
help of a needle, and the filter was transferred onto a glass slide.  
8) Each experiment was performed in triplicate with 6 individual donors.  
9) The slides were allowed to dry in the dark and cells were counted under the fluorescence 
microscope with a 10x objective. 
2.10 Chromatin immunoprecipitation assay (ChIP) 
2.10.1 Cross-linking and cell harvesting 
1) 10-15 million monocytes were plated in a 10cm cell culture Petri dish and cultured for 6 
days in normal and high glucose conditions. 
2) On day 6, conditioned medium was partially discarded. 5ml of the medium was left in the 
Petri dishes.  
3) A total volume 312 µl of 16% Formaldehyde was added dropwise directly to the remaining 
medium to reach a final concentration of 1% and gently rotated at room temperature for 10 
min.  
4) 1M of glycine was prepared with ddH2O water and added to the medium to make a final 
concentration of 325mM and incubated with shaking for 5min at RT. 
5) The cells were washed 2X with 10 ml cold PBS.  
6) The cells were scraped in 5 ml of cold PBS and transferred into a 10 ml tube. 
7) The collected cells were centrifuged for 10 min at 420 g. 
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8) The supernatant was carefully aspirated, and the pellet was resuspended in ChiP lysis 
buffer (750µl per 10-15 million cells). 
2.10.2 Sonication  
1) The cell lysates were sonicated to shear DNA to an average size between 200 to 1000 bp. 
This step has to be optimised for different subtypes of macrophages. 
2) In a biorupture sonicator, 15 cycles were used to sonicate the M1 macrophage samples. 
3) After sonication, the samples were centrifuged for 10 min, 4°C, 8000 g. 
4) Supernatants were transferred to a new 2 ml Eppendorf tube and used for 
immunoprecipitation (IP). The samples were stored at -80°C. 
5) An aliquot of 50µl for each sonicated sample, containing fragmented chromatin 
(“Chromatin sample”) was used as an input for the qRT-PCR control and was used to 
measure the DNA concentration and identify fragment size by gel electrophoresis.  
2.10.3 Determination of amount of DNA and size of DNA fragments  
1) The sonicated chromatin samples were used to calculate the concentration of DNA for 
subsequent IPs and measure DNA fragment size. 
2) 70µl of elution buffer was added to the 50µl of “Chromatin sample”. 
3) 2µl of RNase A (0.5mg/ml) was added. 
4) In order to remove the cross-links, the sample was incubated at 65°C with shaking 
overnight. 
5) 2µl of RNase A (10mg/ml) and 2µl proteinase K (20mg/ml) were added and incubated at 
45°C for 1hour. 
6) Fragmented DNA was purified using QIAquick PCR Purification Kit according to the 
manufacturer’s instructions. The final DNA was eluted in EB buffer. The concentration was 
determined with a Tecan Infinite 200. 
7) The samples were stored at -20°C. 
2.10.4 Immunoprecipitation 
1) Sonicated chromatin samples were allocated equally to all the tubes (one tube per 
antibody).  
2) Each sample was diluted 1:10 with RIPA buffer.  
3) 4µg of primary antibody was added to each sample and incubated at 4°C for 1 hour with 
rotation. 
4) For each specific antibody, an immunoprecipitation reaction using isotype matching IgG 
control was done in parallel.  
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5) Preparation of protein A/protein B beads: Salmon sperm DNA coated Protein A (Merck 
Millipore, Germany) and Salmon sperm DNA coated Protein G (Merck Millipore, Germany) 
were mixed equally and washed three times with RIPA buffer. 
6) RIPA buffer was added at twice the volume of beads.  
7) 100µl of protein A/G beads were added to all the samples and incubated overnight with 
rotation at 4°C.  
8) Immunoprecipitated samples were centrifuged for 3 min at 1000 g and the supernatant was 
discarded.  
9) The following washings were performed: once in low salt wash buffer, once with high salt 
wash buffer, once in LiCl wash buffer.  
10) After each wash, samples were centrifuged for 3 min at 1000 g and supernatants were 
discarded. 
2.10.5 Elution and removal of cross-linking 
1. The DNA was eluted by adding 150µl of elution buffer to the protein A/G beads and 
vortexed slowly for 20 min at 30°C. 
2. The tubes were centrifuged for 3 min at 1000 g and the supernatants were collected into 
fresh tubes. 
3. 10µl of 5M NaCl was added to the supernatants and incubated at 65°C overnight with 
shaking. 
4. 2 µl RNase A (10 mg/ml) and 2 µl proteinase K (20 mg/ml) were added and incubated 
while shaking at 45°C for 1 hour. 
5. The DNA was purified using the QIAquick PCR Purification Kit according to the 
manufacturer’s instructions.  
6. The samples were stored at -20°C.   
2.10.6 ChIP-qPCR 
1. The amount of precipitated genomic DNA concentration was measured with a Tecan 
Infinite 200. 
2. All the samples were diluted to make 1ng concentration of DNA, including IgG and input 
sample DNA. Relative expression of qChIP was normalised to IgG. 
3. Primers and probes were designed using online tools. Diluted genomic DNA were 
quantitatively measured by real-time PCR. 
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2.10.7 ChiP antibodies 
Table 3. Antibodies used for ChiP assay. 
Name of the antibody Name of the Company 
H3K4me1 Abcam (Cat N ab8895) 
H3K4me3 Merck Millipore (Cat N 07-473) 
H3K9me3 Merck Millipore(Cat N 17-625) 
H3K27me3 Merck Millipore(Cat N 17-622) 
acetylated H3 Merck Millipore(Cat N 06-599) 
 
2.11 Statistical analysis 
2.11.1 Statistical analysis for qRT-PCR-and migration assays  
To define the significance of the difference between groups of experimental data, paired two-
tailed t-tests were performed using Microsoft Excel 2010. A p-value less than 0.05 was 
considered statistically significant. Standard error mean (SEM) was calculated for error bars.  
2.11.2 Statistical analysis for Affymetrix Chip assay 
Statistical analysis of microarray data was done by Dr. Carsten Sticht from the Affymetrix 
Core Facility of the Medical Research Centre, Medical Faculty Mannheim. For statistical 
analysis of differential expression during the microarray assay, the SAS software package 
microarray solution, version 1.3 was used. To map the probes to genes, a custom chip 
definition file was applied. Gene expression was analysed using a log-linear mixed model of 
perfect matches. To set the level of significance, a false discovery rate of a=0.05 with 
Bonferroni-correction for multiple testing was applied.  
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3. Results 
3.1 Design of an in vitro model system to examine the effect of 
hyperglycaemia on the activation of primary human macrophages 
To analyse the detrimental effect of high glucose on the differentiation and activation of 
monocytes and macrophages, a unique model system based on primary human monocyte-
derived macrophages was established. CD14+ primary human monocytes isolated out of 
buffy coats were cultivated in serum–free medium (SFM). The SFM medium was produced 
on custom request as glucose free and supplemented with 5mM or 25mM glucose prior to use. 
M-CSF at a concentration of 5 ng/ml was added to optimise viability of macrophages in 
culture conditions. Three prototypes of macrophage subpopulations were generated 
subsequently: M0 (no cytokine stimulation), M1 (stimulated with IFNgamma) and M2 
(stimulated with IL4). The general experimental design is schematically illustrated in Figure 
11. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Schematic diagram of model system developed to analyse macrophage responses to 
hyperglycaemia. Monocytes were isolated from buffy coats using density gradient centrifugation 
followed by CD14+ magnetic separation. Monocytes were cultivated in serum-free SFM medium 
supplemented with M-CSF (5 ng/ml) in the presence of normal glucose (NG, 5mM) or high glucose 
(HG, 25mM). M0: no additional cytokines added; M1: stimulated with IFNg; M2: stimulated with 
IL4. Gene expression was analysed on day 6 of cultivation by RT-PCR and DNA microarray. 
Secretion of cytokines was analysed in the supernatants harvested after 6h, 24h, 3 days and 6 days. 
The presence of histone marks on the promoter of selected genes were analysed by chromatin 
immunoprecipitation (ChIP) on day 6. Transmigration toward inflammatory stimuli was analysed in 
trans-well assays on day 6.  
 
Buffy coat 
 
CD14+ monocytes  
NS  IFNg IL4 
(M0) (M1) (M2) 
 
NG 
 
HG 
 
   
NG 
  
HG 
 
  
NG HG 
Techniques used: RT-PCR, ELISA, DNA microarray, ChIP assay, trans-well assay 
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3.2   Effect of hyperglycaemia on TNF-alpha production in M0, M1 and M2 
macrophages 
TNF-alpha is a key inflammatory cytokine produced by macrophages, and its production is 
stimulated by IFNgamma (Martinez and Gordon, 2014a). Elevated TNF-alpha levels were 
found in diabetic conditions in humans (Mirza et al., 2012) and rats (Quan et al., 2011). 
However, it remains unclear whether hyperglycaemia can be an inducing factor for 
macrophages to continuously produce TNF-alpha in patients with metabolic syndrome and 
diabetes. The effect of hyperglycaemia on TNF-alpha release was examined in M0, M1 and 
M2 macrophages derived from eight individual donors. The inducing effect of 
hyperglycaemia on TNF-alpha secretion was found in 5 out of 8 analysed donors in M0, in 4 
out of 8 donors in M1, and in 1 out of 8 donors in M2 (Figure 12). The effect was stronger 
after 24 hours of macrophage cultivation (up to 0.5 to 4 times elevation in M0 and 4 times in 
M1, Figure 12). The stimulatory effect of hyperglycaemia declined after 3 days and 6 days of 
macrophage cultivation (Figure 12). However, hyperglycaemia didn’t show a stimulatory 
effect on TNF-alpha secretion from day 1 until day 6 in 3 donors in M0, 4 donors in M1 and 7 
donors in M2 (Figure 12). RT-PCR analysis demonstrated that there is only a very slight 
increase (up to 40% in 3 donors) of TNF-alpha gene expression on day 6 (Figure 13). TNF-
alpha is an acute inflammatory response factor induced during the first hours after stimulation 
with exogenous pathogens or adhesion events, therefore, it was further examined whether 
hyperglycaemia has an immediate effect on the gene expression of TNF-alpha (Figure 14). 
The mRNA levels of TNF-alpha in M0, M1 and M2 macrophages obtained from an additional 
6 healthy donors have been analysed after 6 and 24 hours of exposure to hyperglycaemia. The 
stimulatory effect of high glucose on TNF-alpha mRNA levels in M1 after 6 hours was found 
in 5 out of 6 donors (Figure 14). The effect was more pronounced in M1 macrophages with 
the lowest levels of TNF-alpha mRNA in normal glucose conditions (Figure 14, donor 12 (2 
times) and donor 13 (3.5 times)). The stimulatory effect of high glucose in M1 was not 
detectable after 24 hours, suggesting the activation of a classical negative feedback induced 
by acute inflammatory responses (Hu and Ivashkiv, 2009). These data indicate that 
hyperglycaemia has a clear stimulatory effect on TNF-alpha gene expression and release in 
primary human monocyte-derived macrophages, and this effect is more pronounced in INFg 
stimulated M1 macrophages. 
 
 Results 
 
 
  54 
 
 
 
F
ig
u
re
 1
2
. 
E
ff
ec
t 
o
f 
h
y
p
er
g
ly
ca
em
ia
 o
n
 T
N
F
-a
lp
h
a
 s
e
cr
et
io
n
 i
n
 p
ri
m
a
ry
 h
u
m
a
n
 M
0
, 
M
1
 a
n
d
 M
2
 m
a
cr
o
p
h
a
g
es
 i
n
 
n
o
rm
a
l 
a
n
d
 
h
ig
h
 
g
lu
co
se
 
co
n
d
it
io
n
s 
S
u
p
er
n
at
an
ts
 
w
er
e 
co
ll
ec
te
d
 
o
n
 
d
ay
 
1
, 
3
 
an
d
 
6
. 
E
L
IS
A
 
an
al
y
si
s 
o
f 
T
N
F
-a
lp
h
a 
p
ro
d
u
ct
io
n
 b
y
 d
if
fe
re
n
tl
y
 s
ti
m
u
la
te
d
 m
ac
ro
p
h
ag
es
 w
as
 m
ea
su
re
d
 i
n
 n
o
rm
al
 g
lu
co
se
 (
N
G
, 
5
m
M
) 
an
d
 h
ig
h
 g
lu
co
se
 (
H
G
, 
2
5
m
M
) 
co
n
d
it
io
n
s.
 A
ll
 e
x
p
er
im
en
ts
 w
er
e 
p
er
fo
rm
ed
 i
n
 d
u
p
li
ca
te
s.
 T
h
e 
re
su
lt
s 
ar
e 
p
re
se
n
te
d
 f
o
r 
in
d
iv
id
u
al
 d
o
n
o
rs
 (
n
=
8
) 
in
 
n
o
rm
al
 a
n
d
 h
ig
h
 g
lu
co
se
 c
o
n
d
it
io
n
s.
  
N
S
 (
M
0
),
 I
F
N
g
 (
M
1
) 
an
d
 I
L
4
 (
M
2
).
  
 
 Results 
 
 
  55 
 
 
Figure 13. Effect of hyperglycaemia on TNF-alpha mRNA expression on day 6 of macrophage 
cultivation. RT-PCR analysis of TNF-alpha mRNA expression in differently stimulated macrophages 
cultured in normal (NG, 5mM) and high glucose (HG, 25mM) condition for 6 days. The experiments 
were performed in duplicates. Individual donors are indicated as Donor 1 to Donor 8. NS (M0), IFNg 
(M1) and IL4 (M2). 
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Figure 14. Effect of hyperglycaemia on TNF-alpha mRNA expression in macrophages after 6h 
and 24h. RT-PCR analysis of TNF-alpha mRNA expression in monocytes without cytokine 
stimulation (NS) and stimulated with IFNg or IL4. Cultivation was done for 6h and 24h in normal 
(NG, 5mM) and high glucose (HG, 25mM) conditions. The experiments were performed in duplicates. 
Individual donors are indicated as Donor 9 to Donor 14.  
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3.3 Hyperglycaemia leads to increased gene expression and secretion of 
IL-1beta in human M0, M1 and M2 
IL-1beta is an inflammatory cytokine known to be produced by IFNgamma stimulated 
macrophages, and is considered as a marker for M1 macrophages (Kzhyshkowska et al., 
2016; Martinez and Gordon, 2014b). Therefore, it was next examined how hyperglycaemia 
affects differentiation of macrophages towards a pro-inflammatory phenotype by ELISA 
analysis of IL-1beta release on day 6. As expected, the highest IL-1beta levels are produced 
by M1 macrophages stimulated with IFNgamma (Figure 15). Hyperglycaemia increased IL-
1beta release on all days analysed (day 1, 3 and 6) in 7 out of 8 donors, ranging from 0.5 to 
3.2 times in M1. Hyperglycaemia also had an inducing effect on IL-1beta release in M0 and 
M2, with the strongest effect on donors 1, 2, 5 and 7 (Figure 15). RT-PCR analysis 
demonstrated that hyperglycaemia had an inducing effect on the gene expression level of IL-
1beta in M1 (on day 6) in 4 out of 8 donors (donors 1, 2, 3, and 5) (Figure 16). Next, it was 
examined whether high glucose has an immediate effect on the stimulation of IL-1beta gene 
expression (Figure 17) and secretion (Figure 18). Monocytes derived from 6 donors have been 
analysed for IL-1beta mRNA levels and cytokine release after 6 and 24 hours of exposure to 
hyperglycemic conditions. In all analysed donors, we found the stimulatory effect of high 
glucose on IL-1beta mRNA levels in M1 after 6 hours, and the strongest response was 
detected in donor 10 (89 times increase) (Figure 17). After 6 h, hyperglycaemia also 
stimulated IL-1beta expression in M0 of all analysed donors as well as in M2 in 5 out of 6 
donors (Figure 17). Taken together, the stimulatory effects of hyperglycaemia were strongly 
pronounced in M0 and M1 macrophages. The total levels of mRNA differ between donors 
with highest (17A), intermediate (17B), and lowest (17C) expression levels in 
hyperglycaemic conditions. An induction of IL-1beta release was detected in M0, M1 and M2 
in 4 out of 6 donors after 6 h and 24 h, mostly corresponding to the HG-induced IL-1beta 
RNA levels (Figure 18). 
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Figure 16. Effect of hyperglycaemia on IL-1beta mRNA expression on day 6 of macrophage 
cultivation. RT-PCR analysis of IL-1beta mRNA expression in differently stimulated macrophages 
cultured in normal (NG, 5mM) and high glucose (HG, 25mM) conditions for 6 days. The experiments 
were performed in duplicates. Individual donors are indicated as Donor 1 to Donor 8. 
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Figure 17. Effect of hyperglycaemia on IL-1beta mRNA expression in macrophages after 6h and 
24h. RT-PCR analysis of IL-1beta mRNA expression in monocytes without cytokine stimulation 
(NS), stimulated with IFNgamma or IL4. Cultivation was done for 6h and 24h in normal (NG, 5mM) 
and high glucose (HG, 25mM) conditions. The experiments were performed in duplicates. Individual 
donors are indicated as Donor 9 to Donor 14. (A) Donors 10 and 11 with highest mRNA levels of IL-
1beta in HG; (B) Donors 9 and 14 with intermediate mRNA levels of IL-1beta in HG, and (C) Donors 
12 and 13 the lowest mRNA levels of IL-1beta in HG. 
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Figure 18. Effect of hyperglycaemia on IL-1beta secretion in primary human M0, M1 and M2 
macrophages in normal and high glucose conditions. Supernatants of macrophages cultured in NG 
and HG conditions were harvested after 6h and 24h. Concentrations of secreted IL-1beta were 
measured by ELISA. All measurements were performed in duplicates. The results are presented for 
individual donors (n=6) in NG and HG conditions. Non-stimulated (NS), IFNgamma-stimulated and 
IL4 stimulated macrophages were analysed.  
 
 
3.4 High glucose can induce IL-1Ra release in human M0, M1 and M2 
independent of gene expression activation 
IL-1Ra is a cytokine produced by macrophages in response to IL4, known to block the pro-
inflammatory effects of IL-1beta (Palomo et al., 2015 38). However, elevated levels of IL-
1Ra were found to be associated with increased risk of developing type 2 diabetes (Carstensen 
et al., 2010). IL-1Ra is suggested to be involved in the inflammatory responses in prediabetes 
(Herder et al., 2009), and the role of IL-1Ra in diabetic complications remains to be 
controversial. However, IL-1Ra is considered as a marker cytokine for M2 macrophages. 
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Therefore, it was next examined how hyperglycaemia affects the differentiation of 
macrophages towards M2 by the analysis of IL-1Ra release on day 6. The highest IL-1Ra 
levels were produced by M2, stimulated with IL4 on day 6 (Figure 19). Hyperglycaemia 
increased the release of IL-1Ra in M2 on all days analysed (day 1, 3 and 6). The stimulatory 
effect of HG increased up to day 6 in 5 out of 8 donors (donors 1, 2, 5, 6 and 8) ranging from 
0.5 to 3 times (Figure 19). Hyperglycaemia also strongly induced IL-1Ra release in M0 and 
M1 macrophages, with the strongest effect on day 6 observed in M0 for donors 1, 3, 4, 5 and 
7 (Figure 19). In M1 macrophages, the inducing effect of HG on the IL-1Ra release was 
found in donor 5 (Figure 19). RT-PCR analysis demonstrated that on day 6, hyperglycaemia 
did not show any significant effect on IL-1Ra gene expression (Figure 20). Therefore, it was 
considered that elevated levels of secreted IL-1Ra on day 6 are a result of the accumulation of 
the cytokine in the medium. It was hypothesised that expression of IL-1Ra mRNA is induced 
at an early stage of macrophage differentiation as an immediate response of exposure to HG 
conditions, and is already downregulated on day 6. Therefore, it was examined whether high 
glucose has an immediate effect on the stimulation of IL-1Ra gene expression (Figure 21) and 
secretion (Figure 22). The mRNA levels, as well as the cytokine release of IL-1Ra of 
monocytes derived from 6 healthy donors, were analysed after 6 and 24 hours of exposure to 
HG in M0, M1 and M2 conditions. In 4 out of 6 donors (donors 9, 10, 11 and 13) the 
stimulatory effect of high glucose on IL-1Ra mRNA levels was found in M0, M1 and M2 
after 6 hours. Donor 12 didn’t show an elevated mRNA expression level in M1, but in M0 
and M2 (Figure 21). The induction mediated by HG was more pronounced in M1 
macrophages compared to M0 and M2 with the highest upregulation up to 88 times in donor 
11 (Figure 21). After 6 hours, ELISA demonstrated the stimulatory effect of hyperglycaemia 
on IL-1Ra release in M1 and M2 in all 6 donors, and in M0 in 5 out of 6 donors (Figure 22). 
After 24 hours the stimulatory effect of hyperglycaemia was observed in M0, M1 and M2 in 
all donors (Figure 22). In summary, these data demonstrate that hyperglycaemia has a 
stimulatory effect on the IL-1Ra gene expression and release, independent of IL4, and the 
inducing effect of IL4 strongly depends on high glucose levels.   
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Figure 20. Effect of hyperglycaemia on IL-1Ra mRNA expression on day 6 of macrophage 
cultivation. RT-PCR analysis of IL-1Ra mRNA expression in differently stimulated macrophages 
cultured in normal (NG, 5mM) and high glucose (HG, 25mM) conditions for 6 days. The experiments 
were performed in duplicates. Individual donors are indicated as Donor 1 to Donor 8. 
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Figure 21. Effect of hyperglycaemia on IL-1Ra mRNA expression in macrophages after 6h and 
24h. RT-PCR analysis of IL-1Ra mRNA expression in macrophages without cytokine stimulation 
(NS), stimulated with IFNg or IL4. Cultivation was done for 6h and 24h in normal (NG, 5mM) and 
high glucose (HG, 25mM) conditions. The experiments were performed in duplicates. Individual 
donors are indicated as Donor 9 to Donor 14. 
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Figure 22. Effect of hyperglycaemia on IL-1Ra secretion in primary human M0, M1 and M2 
macrophages in normal and high glucose conditions. Supernatants of macrophages cultured in NG 
and HG conditions were harvested after 6h and 24h. Concentrations of secreted IL-1Ra were measured 
by ELISA. All measurements were performed in duplicates. The results are presented for individual 
donors (n=6) in normal and high glucose conditions. Non-stimulated (NS), IFNgamma-stimulated and 
IL4 stimulated macrophages were analysed. 
 
3.5  High glucose suppresses CCL18 production in human 
monocytes/macrophages 
CCL18 is one of the cytokines expressed by M2 macrophages upon stimulation with IL4 in 
late stages of macrophage differentiation (Kodelja et al., 1998). Therefore, it was next 
examined how hyperglycaemia affects differentiation of macrophages towards M2 by analysis 
of CCL18 expression. M0, M1 and M2 of 8 individual donors were analysed for CCL18 gene 
expression on day 6. RT-PCR analysis demonstrated that hyperglycaemia has a suppressive 
effect on CCL18 expression in M2 of all 8 donors (range between 0.24 to 16.7 times) (Figure 
23). In M0 and M1, the levels of CCL18 mRNA were very low in both NG and HG 
conditions. Next, it was investigated whether HG has an effect on the release of CCL18. 
CCL18 secretion levels were measured on days 1, 3 and 6 by ELISA (Figure 24). The IL4 
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stimulated macrophages secreted a high amount of CCL18 on day 6 of cultivation under 
normal glucose conditions. Hyperglycaemia suppressed CCL18 release on day 6 in most of 
the donors in M2 macrophages (Figure 24). Hyperglycaemia had a slightly inducing effect of 
CCL18 release on day 6 in M0, however the absolute levels of secreted CCL18 in M0 were 
very low compared to M2, and biologically not significant. The suppression mediated by HG 
on CCL18 mRNA levels and cytokine release in M2 correlated for most of the donors. The 
suppressive effect of HG on CCL18 was much more pronounced on the level of gene 
expression compared to the levels of secreted cytokine. The suppression was most prominent 
in M2 of donors with the lowest base values of CCL18 mRNA levels under normal glycaemic 
conditions on day 6.  
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Figure 23. Effect of hyperglycaemia on CCL18 mRNA expression on day 6 of macrophage 
cultivation. RT-PCR analysis of CCL18 mRNA expression in differently stimulated macrophages 
cultured in normal (NG, 5mM) and high glucose (HG, 25mM) conditions for 6 days. The experiments 
were performed in duplicates. Individual donors are indicated as Donor 1 to Donor 8. 
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3.6 Identification of genes induced by hyperglycaemia using Affymetrix 
DNA microarray 
Analysis of the cytokine profile demonstrated that hyperglycaemia has not only simple pro-
inflammatory effects on macrophage activation, but rather a complex mode of programming 
towards a chronic inflammatory state. Affymetrix GeneChips microarray was applied in order 
to identify the transcriptional program induced by hyperglycaemia in human primary M0, M1 
and M2. Macrophages were cultivated in normal and hyperglycaemic conditions for 6 days. 
Macrophages from 4 donors (donors 1-4) with the strongest response to hyperglycaemia 
according to the suppression of CCL18 were used in the analysis. The total amount of genes 
differentially expressed in normal and hyperglycaemic conditions are demonstrated in Figure 
25. A total of 2546 genes were differentially regulated by hyperglycaemia. Thereof 1173 
genes were found statistically significant in M0 (NS), 1574 genes in M1 (IFNgamma) and 16 
genes in M2 (IL4). Microarray analysis also determined that hyperglycaemia-induced 
differential regulation of 207 common genes in M0 (NS) and M1 (IFNgamma), 2 common 
genes in M1 (IFNgamma) and M2 (IL4), 1 common gene in M0 (NS) and M2 (IL4), and 2 
common genes for all 3 activation states of macrophages (Figure 25).    
The Gene Set enrichment analysis (GSEA) database was used to define the gene families. The 
Microsoft office excel VBA scripts were used to track the genes with a statistically significant 
difference (P ≤ 0.05) in expression comparing normal and hyperglycaemic conditions. The 
major families of genes upregulated in hyperglycemic conditions are listed in Table 4 and 
included families of chemokines and cytokines that also included cytokine receptors (20 
members), the ribonuclease RNase A family (9 members), the solute carrier family (28 
members), the S100 calcium binding protein family (8 members), the transmembrane protein 
family (20 members) and the zinc finger family (37 members). The complete microarray data 
was deposited in the Gene Expression Omnibus database (GEO) with accession number 
GSE86298. 
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Figure 25. Affymetrix DNA microarray analysis of gene expression in macrophage cultured in 
NG and HG conditions for 6 days. Venn diagram of differentially expressed genes in macrophages 
cultured with NG and HG conditions. Each number represents the number of genes differentially 
expressed in response to hyperglycaemia. Each circle represents a population of macrophages with a 
different stimulation (Green – M0 (NS), Red – M1 (IFNgamma), Blue – M2 (IL4). Intersecting points 
represent the number of genes differentially regulated by hyperglycaemia in 2 or more stimulations. 
 
Table 4. Families of genes upregulated by high glucose in human macrophages. 
Gene Family No. of genes 
affected by HG 
Most strongly affected family 
member 
M0 M1 M2  
Chemokines and Cytokines  2 18 0 CCR2 > 7.1 fold change (M1) 
Ribonuclease, RNase A  family  6 3 0 RNASE2 > 5 fold change (M0) 
Solute carrier family 11 17 1 SLC4A7 > 1.8 fold change (M1) 
S100 calcium binding protein  
family 
1 7 0 S100A12 > 4.4 fold change (M1) 
Transmembrane protein family  8 12 0 TMEM130 > 3.6 fold change (M1) 
Zinc finger family 17 19 1 ZMYM3 > 1.8 fold change (M1) 
 
M1 (IFNg): HG vs NG M0 (NS): HG vs NG 
M2 (IL4): HG vs NG 
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Affymetrix microarray analysis revealed that hyperglycaemia induces expression of IL-1beta 
in M1 (3 fold change, P=0.0002) and M0 (1 fold change, P=0.9), which confirmed the results 
of the previous analysis by RT-PCR and ELISA. The strongest upregulating effect of 
hyperglycaemia within the family of cytokines and cytokine receptors was found for CCR2 
[M0 (4.2 fold change, p=0.01) and M1 (7.1 fold change, p= 0.0008)]. 
Chemokine receptor CCR2 is the major receptor for monocyte chemoattractant protein 1 
MCP1 (CCL2), and interaction of CCL2 with CCR2 expressed on monocytes is responsible 
for monocytes recruitment to the sites of inflammation, including fat tissues in obesity and 
vascular complications (Ali et al., 2008; Chu et al., 2014; Weisberg et al., 2006). In one study, 
it was demonstrated that silencing of CCR2 expression reduces the infiltration of 
macrophages into inflamed adipose tissue in a mouse model (Kim et al., 2016). The 
CCL2/CCR2 system was shown to be important for vascular complications such as 
atherosclerosis (Feria and Díaz-González, 2006).Therefore, CCR2 was selected to examine 
the effects of hyperglycaemia on its expression regulation and functional role in macrophage 
recruitment. 
3.7 RT-PCR analysis of CCR2 expression in hyperglycaemic conditions 
To confirm the results obtained by microarray analysis, expression of CCR2 was further 
examined by RT-PCR (Figure 26). CCR2 gene expression was analysed in M0, M1 and M2 
of 8 individual donors. M0, M1 and M2 were cultivated in normal and hyperglycaemia 
conditions for 6 days (as illustrated by Figure 11). RT-PCR analysis of macrophages isolated 
from 8 individual donors (donor 1-8) demonstrated that hyperglycaemia induced an 
upregulation of CCR2 gene expression in M0 4.6 times (P=0.055) and in M1 3.8 times 
(P=0.012) (Figure 26). CCR2 gene expression was increased in hyperglycaemic conditions in 
M0 and M1 of all donors analysed, ranging from 1.7 to 35.7 times for M0, and 1.4 to 12.3 
times in M1 (Figure 28). In M2, the levels of CCR2 mRNA were very low in both NG and 
HG conditions (Figure 26). CCR2 was shown to be expressed in monocytes and is responsible 
for monocyte response to MCP1/CCL2. RT-PCR analysis of 5 individual donors (donor 4-8) 
demonstrated that monocytes express much lower levels of CCR2 mRNA compared to M0 
and M1 in HG conditions, indicating that hyperglycaemia induces CCR2 expression during 
monocyte to macrophage differentiation (Figure 27).  
 
 
 Results 
 
 
  73 
 
 
  
Figure 26. Effect of hyperglycaemia on CCR2 mRNA expression on day 6 of macrophage 
cultivation. RT-PCR analysis of CCR2 mRNA expression in differently stimulated macrophages 
cultured in normal (NG, 5mM) and high (HG, 25mM) glucose conditions. Each column represents the 
mean ± SEM normalised to 18srRNA levels. The experiments for each donor were performed in 
duplicates (total number of donors n=8). 
 
   
Figure 27. Comparison of CCR2 mRNA expression between monocytes and mature 
macrophages cultured in normal and hyperglycaemic conditions. CCR2 mRNA expression in 
freshly isolated monocytes (Mon) and differently stimulated macrophages cultured in NG and HG 
conditions for 6 days was analysed by RT-PCR. Each column represents the mean ± SEM normalised 
to 18srRNA levels. Monocytes and macrophages from 5 individual donors were analysed. The RT-
PCR experiments for each donor were performed in duplicates (total number of donors n=5). 
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Figure 28. Effect of hyperglycaemia on CCR2 mRNA expression on day 6 of macrophage 
cultivation. RT-PCR analysis of CCR2 mRNA expression in differently stimulated macrophages 
cultured in NG and HG condition for 6 days. The experiments were performed in duplicates. 
Individual donors are indicated as Donor 1 to Donor 8.  
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3.8 Hyperglycaemia facilitates macrophage migration towards CCL2 
To address the functional relevance of elevated expression of CCR2 in hyperglycaemic 
conditions, migration of M0 and M1 generated in normal and high glucose conditions towards 
a CCL2 gradient was analysed. The migration assay was performed with a transwell system 
with a 5-µm pore size membrane. Macrophages were cultivated in normal (NG) or 
hyperglycaemia (HG) conditions in the absence of cytokines (M0) or under stimulation of 
IFNgamma (M1) as illustrated in Figure 11. On day 6, macrophages were collected and 1 x 
10
5
 were seeded in serum-free medium in the upper chamber of a transwell, while CCL2 was 
added to the lower chamber at a concentration of 100 ng/ml. After 16h incubation, migrated 
cells on the lower surface of the membrane were fixed, stained with DAPI and quantified with 
image J. Analysis of M0 and M1 from 5 independent donors demonstrated that CCL2 induced 
migration was strongly stimulated by hyperglycaemia (Figure 29). For M0 macrophages, the 
stimulatory effect of hyperglycaemia was 7.6 times (P=0.007), and for M1 it was increased 
11.2 times (P=0.001) (Figure 29). Next, it was hypothesised that elevated expression of CCR2 
induced by hyperglycaemia can make macrophages more sensitive to lower concentrations of 
CCL2. Therefore, a range of different concentrations of CCL2 (100 ng/ml, 25 ng/ml, 6.25 
ng/ml and 1.56 ng/ml) was examined for the ability to induce migration of M1 macrophages 
in a transwell system for 3 additional donors. For 100 ng/ml CCL2, the stimulatory effect of 
hyperglycaemia on M1 macrophages was 11.3 times (P=0.15), for 25 ng/ml CCL2 it was 14.4 
times (P=0.057), for 6.25 ng/ml CCL2 it was 11.6 times (P=0.036) and for 1.56 ng/ml CCL2 
it was 8.4 times (P=0.0059) (Figure 30).These data indicate that even very low concentrations 
of CCL2 can induce migration of inflammatory macrophages in hyperglycemic conditions. 
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Figure 29. Effect of hyperglycaemia on M0 and M1 trans-migration induced by CCL2. 
Macrophages were cultured in NG and HG conditions in the absence of stimulation (NS) or the 
presence of IFNgamma for 6 days. The migration assay was performed in a transwell system with 
CCL2 (added to the lower chamber at the concentration of 100 ng/ml). Data are presented for 
macrophages of individual donors. 
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Figure 30. Effect of hyperglycaemia on M1 trans-migration towards different concentrations of 
CCL2. Macrophages were cultured in NG and HG conditions under stimulation with IFNgamma for 6 
days. The transwell migration assay was performed in a transwell system using a range of 
concentrations of CCL2 (100 ng/ml, 25 ng/ml, 6.25 ng/ml and 1.56 ng/ml) in the lower chamber. The 
total amount of donors analysed (n=3).  
 
3.9 Epigenetic regulation of CCR2 and IL-1beta expression 
An increasing number of studies demonstrate that epigenetic mechanisms contribute to the 
development of diabetic vascular complications (Prattichizzo et al., 2015b; Reddy et al., 
2015). The histone code that controls chromatin structure was shown to be affected by 
diabetic conditions in endothelial cells (Prattichizzo et al., 2015b; Reddy et al., 2015). 
Increased acetylation of histone H3 and mono and tri-methylation of H3 at K4 (lysine 4) are 
associated with gene activation (Heintzman et al., 2007; Kim et al., 2005; Koch et al., 2007), 
while increased tri-methylation of H3 at K9 or K27 (lysine 9 or 27) were linked with gene 
repression (Heintzman et al., 2007).  
Since hyperglycaemia has strong effects on the expression of CCR2 and IL-1beta (section 3.3 
and 3.7), the promoters of these genes were selected for the analysis of the histone code under 
hyperglycemic conditions. Bioinformatic analysis of CCR2 and IL-1beta promoters using 
Roadmap Epigenomics Visualization Hub (VizHub)) was used to select the histone marks. 
Three activating histone marks (H3K4me1, H3K4me3 and acetylated H3) and 2 repressing 
histone marks (H3K9me3 and H3K27me3) were chosen for chromatin immunoprecipitation 
experiments. 
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3.10  Effect of hyperglycaemia on the presence of histone marks on the 
CCR2 promoter 
The impact of hyperglycemic conditions on histone modifications at the CCR2 promoter was 
studied with the Chromatin Immuno Precipitation assay (ChIP). Macrophages were cultivated 
in normal (NG) or hyperglycaemia (HG) conditions in the presence of IFNgamma (M1) as 
illustrated in Figure 11. On day 6, macrophages were treated with formaldehyde in order to 
cross-link the DNA with protein (chromatin). The cross-linked chromatin was sonicated in 
order to obtain fragments with a size between 200-1000bp. Fragmented chromatin was 
incubated overnight at 4 degrees with specific antibodies against: 1) acetylated H3 (Acetyl 
H3), 2) monomethylation of lysine 4 on histone H3 (H3K4me1), 3) trimethylation of lysine 4 
on histone H3 (H3K4me3), 4) trimethylation of lysine 9 on histone H3 (H3K9me3) and 5) 
trimethylation of lysine 27 on histone H3 (H3K27me3). The immune-complex was collected 
by Protein A/G beads and precipitated DNA was purified. The purified DNA was quantified 
by RT-PCR (qChIP). qChIP analysis of M1 macrophages demonstrated that levels of 
H3k4me1 (p=0.006, n=10) (Figure 31a) and H3K4me3 (p=0.008, n=10) (Figure 31b) 
significantly increased under HG compared to NG conditions at the CCR2 promoter. An 
increase in Acetyl H3 (Figure 31c) was observed, however it didn’t reach significance 
(p=0.13, n=4). Hyperglycaemic conditions didn’t affect H3K9me3 (p=0.42, n=6) (Figure 31d) 
and H3K27me3 (p=0.78, n=6) (Figure 31e). The present data provides the evidence that 
hyperglycaemic conditions induce a dramatic increase in the expression of the CCR2 gene 
along with epigenetic modifications in the nucleus. 
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Figure 31. Analysis of histone marks associated with the CCR2 promoter using qChIP. ChIP was 
done using antibodies specific for a) histone H3 monomethylated at lysine 4 (H3K4me1), b) histone 
H3 trimethylated at lysine 4 (H3K4me3), c) acetylated histone H3 (AcH3), d) histone H3 
trimethylated at lysine 9 (H3K9me3) and e) histone H3 trimethylated at lysine 27 (H3K27me3) at the 
CCR2 promoter in primary human M1 macrophages cultured in NG and HG. RT-PCR was used to 
amplify the CCR2 promoter fragment. Each column represents the mean ± SEM. (n=4-10 (which is 
mentioned in Figure) donors per group; three independent experiments), fold change compared to IgG.  
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3.11 Histone modification levels correlate to CCR2 gene expression in M1 
macrophages 
It is known that histone activation marks are indicative of the formation of transcriptionally 
active chromatin. It was next verified whether the activating histone marks identified on the 
promoter of CCR2 gene lead to an increase in CCR2 expression.  
The ChIP assay for histone mark presence on the CCR2 promoter and RT-PCR analysis of 
CCR2 gene expression were performed in parallel for M1 macrophages exposed to 
hyperglycaemic conditions derived from four independent healthy donors. In 3 out of 4 
donors (donor 21, 23 and 24), levels of all three histone marks (H3K4me1, H3K4me3 and 
Acetyl H3) on the CCR2 promoter were increased and correlated with a strong upregulation 
of CCR2 gene expression (Figure 32). In donor 22, levels of only two histone marks, 
H3K4me1 and H3K4me3 were increased, and the level of Acetyl H3 was decreased, which 
correlated with only a slight upregulation of CCR2 gene expression (Figure 32). These data 
indicate that cooperative action of all three activating histone marks, H3K4me1, H3K4me3 
and Acetyl H3, is required for efficient stimulation of CCR2 gene expression in 
hyperglycaemic conditions. 
3.12 Effect of hyperglycaemia on the presence of histone marks on the IL-
1beta promoter 
The impact of hyperglycaemic conditions on histone modifications at the IL-1beta promoter 
was studied by ChIP using the same macrophage samples as for analysis of the CCR2 
promoter (Section 3.10). Levels of H3k4me1 (p=0.049, n=10) (Figure 33a) and H3K4me3 (p 
=0.041, n=10) (Figure 33b) on the IL-1beta promoter were significantly increased in M1 
under HG conditions as compared to NG conditions. An increase in Acetyl H3 (Figure 33c) 
was observed, however it wasn’t significant (P=0.063, n=4). Hyperglycaemic conditions 
didn’t affect H3K9me3 (p=0.79, n=6) (Figure 33d) and H3K27me3 (p=0.16, n=6) (Figure 
33e). The present data provides that hyperglycaemic conditions induce the expression of the 
IL-1beta gene along with epigenetic modifications in the nucleus. 
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Figure 32. Comparison of the presence of histone marks on the CCR2 promoter with CCR2 gene 
expression. Macrophages stimulated for 6 days with IFNgamma were used. The left panel shows the 
results of chromatin immunoprecipitation (ChIP) analysis using antibodies for specific histone marks 
(H3K4me1, H3K4me3, AcetlyH3) and the right panel shows the results of RT-PCR. qChIP (fold 
change compared to IgG) and RT-PCR are presented for 4 individual donors (donor 21, 22, 23 and 
24). Each row represents an individual donor. The experiments were performed in triplicates. NG: 
5mM glucose, HG: 25mM glucose. 
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Figure 33. Analysis of histone marks associated with the IL-1beta promoter using qChIP. ChIP 
was done using antibodies specific for a) histone H3 monomethylated at lysine 4 (H3K4me1), b) 
histone H3 trimethylated at lysine 4 (H3K4me3), c) acetylated histone H3 (Acetyl H3), d) histone H3 
trimethylated at lysine 9 (H3K9me3), and e) histone H3 trimethylated at lysine 27 (H3K27me3) at the 
IL-1beta promoter in the primary human M1 macrophages that had been cultured in normal (5mM) 
and High (25mM) glucose. Each column represents the mean ± SEM (n = 4-10 (mentioned in each 
Figure) donors per group; three independent experiments) fold change compared to IgG. 
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3.13 Histone modification levels correlate IL-1beta gene expression in M1 
macrophages 
It was next verified if the activating histone marks identified on the promoter of IL-1beta gene 
correlate with the increase in IL-1beta gene expression.  
The ChIP assay for histone marks present on the IL-1beta promoter and RT-PCR analysis of 
IL-1beta gene expression were performed in parallel for M1 macrophages exposed to 
hyperglycaemic condition derived from four independent healthy donors. In 3 out of 4 donors 
(donor 21, 23 and 24), the levels of all three histone marks, H3K4me1, H3K4me3 and Acetyl 
H3, on the IL-1beta promoter were increased and correlated with the upregulation of IL-1beta 
expression (Figure 34). In donor 22, the level of Acetyl H3 was increased, the level of 
H3K4me1 was not changed (very slight tendency towards increased) and the level of 
H3K4me3 was decreased, which correlated with downregulation of IL-1beta gene expression 
(Figure 34). These data suggest that H3K4me1 and H3K4me3 are required for stimulation of 
IL-1beta gene expression in hyperglycaemic conditions.  
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Figure 34. Comparison of the presence of histone marks on the IL-1beta promoter with IL-1beta 
gene expression in hyperglycaemic conditions. Macrophages stimulated for 6 days with IFNgamma 
were used. The left panel shows the results of chromatin immunoprecipitation (ChIP) analysis using 
antibodies for specific histone marks (H3K4me1, H3K4me3, AcetylH3) and the right panel shows the 
results of RT-PCR. qChIP (fold change compared to IgG) and RT-PCR are presented for 4 individual 
donors (donor 21, 22, 23 and 24). Each row represents an individual donor. The experiments were 
performed in triplicates. NG: 5mM glucose, HG: 25mM glucose. 
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4. Discussion 
4.1   Effect of hyperglycaemia on cytokine production during monocyte to 
macrophages differentiation 
Macrophages play a key role in inflammatory reactions in metabolic syndromes, diabetes and 
vascular complications. However, very limited attention was given until now to the 
investigation of the role of hyperglycaemia as a separate factor in the programming of 
primary human monocyte-derived macrophages. The limitation was caused by the absence of 
a model system to compare the molecular profile and functions of primary human 
macrophages in serum-free conditions in the presence of normal and high glucose. In the 
current study, we have established such a system and first analysed how hyperglycaemia 
affected the production of key cytokines characteristic of the M1 macrophage phenotype 
(TNF-alpha, IL-1beta) and M2 macrophage phenotype (IL-1Ra, CCL18) (Kzhyshkowska et 
al., 2016).  
 
Among the analysed cytokines and chemokines, TNF-alpha production is known to induce 
microvascular complications associated with diabetes (Demircan et al., 2006). In addition to 
triggering acute and chronic inflammation, TNF-alpha controls glucose and lipid metabolism 
and prevents insulin production in pancreatic beta cells (Pickup, 2004). It was previously 
shown that newly diagnosed diabetic patients have increased levels of TNF-alpha in serum 
compared to non-diabetic controls (Lee et al., 2005; Mirza et al., 2012; Stentz et al., 2004). 
However, the cellular sources that contribute to increased circulating TNF-alpha levels are 
still questionable. In this study, it was demonstrated that hyperglycaemia has an immediate 
effect on the stimulation of TNF-alpha expression and secretion in monocytes (6 hours and 24 
hours respectively). Moreover, TNF-alpha secretion during monocyte/macrophage 
differentiation in hyperglycaemic conditions decreased in a time-dependent manner, probably 
reflecting the degradation of already secreted cytokine while no additional secretion was 
induced at later time points when gene expression of TNF-alpha was already down-regulated. 
Thus, monocytes exposed to high glucose in the blood, but not mature macrophages, can be 
the source of increased TNF-alpha levels in the circulation of diabetic patients. 
 
Macrophage-derived IL-1beta induces insulin resistance in obesity, mediates beta-cell 
destruction and impairs insulin secretion (Maedler et al., 2009). In this study, hyperglycaemia 
was found to stimulate both gene expression and release of IL-1beta in M0 and M1 at all 
analysed time points (beginning from 6 hours until 6 days). However, while the inducing 
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effect of hyperglycaemia at early time points was identified for all donors analysed, long-term 
up-regulation of IL-1beta gene expression was found only in part of the donors, suggesting 
additional mechanisms that control IL-1beta release in hyperglycaemic conditions. 
Furthermore, also in M2, hyperglycaemia-induced short-term gene expression of IL-1beta 
(after 6h), while the elevated release of the cytokine was detected up to 6 days. The possible 
explanation for the prolonged stimulatory effect of hyperglycaemia on the release of IL-1beta 
is the involvement of the NLRP3 inflammasome that acts as a platform for the maturation and 
secretion of IL-1beta (Grishman et al., 2012; Stutz et al., 2009). The NLRP3 inflammasome is 
an important sensor of metabolic dysregulation and is involved in the regulation of glucose 
and insulin homoeostasis (Grant and Dixit, 2013). Genetic deletion of components of the 
NLRP3 inflammasome results in improved glucose tolerance of high-fat diet fed mice 
(Vandanmagsar et al., 2011a). It was shown that the NLRP3 inflammasome was involved in 
the progression of diabetes and microvascular complications (Grant and Dixit, 2013; Lee et 
al., 2013; Shi et al., 2015). Our data suggest that hyperglycaemia has an effect on the 
maturation of IL-1beta in the NLRP3 inflammasome, not only in M0 and M1, but also in M2 
macrophages. Of note, IL-1beta secretion levels were not significantly affected by the type of 
macrophage polarisation and were comparable for M0, M1 and M2 macrophages at all 
analysed time points. The data on the upregulation of IL-1beta secretion in hyperglycemic 
conditions are in line with other studies on different cell types such as bovine retinal 
endothelial cells (Kowluru and Odenbach, 2004), LPS-activated human monocytes (Orlinska 
and Newton, 1993), human pancreatic islets (Maedler et al., 2002) and human aortic 
endothelial cells (Asakawa et al., 1997). In contrast to TNF-alpha, IL-1beta production did 
not undergo downregulation by the negative feedback mechanism. A study by Spranger et al. 
demonstrated that increased levels of secreted IL-1beta can predict the development of type 2 
diabetes in obese patients (Spranger et al., 2003). Recently, it was demonstrated that islet 
amyloid induces the production of IL-1beta in cultured human pancreatic islets resulting in 
beta cell apoptosis (Park et al., 2017). In addition, T1DM patients with kidney failure have 
higher levels of pro-inflammatory monocytes and circulatory inflammatory mediators such as 
IL-1beta, IL-1Ra and VEGF compared to patients with T1DM alone (Kolseth et al., 2017). 
Furthermore, bariatric surgery-induced weight loss was shown to reduce IL-1beta expression 
in subcutaneous fat (Moschen et al., 2011). Our data suggest that mature macrophages, even 
being polarised in the M2 direction, can respond to hyperglycaemia by the production of IL-
1beta that supports chronic inflammation in different tissues, including sub-endothelial 
regions and fat tissue.  
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IL-1Ra is one of the main cytokines released by M2 macrophages acting as a natural inhibitor 
of IL-1beta by a competitive binding to the receptor of IL-1beta (IL-1R1), and blocking its 
activation (Palomo et al., 2015). The evidence for the beneficial effect of IL-1Ra was 
provided by application of a recombinant human IL-1Ra (Anakinra) in type 2 diabetic 
patients. Treatment with Anakinra resulted in improved beta cell secretory function; 
normalisation of glycaemic conditions and reduced markers of systemic inflammation C-
reactive protein and IL6 (Larsen et al., 2007). However, the role of IL-1Ra in the development 
of diabetes remains to be controversial since increased levels of IL-1Ra were found to be 
associated with an elevated risk of type 2 diabetes and insulin resistance in the obese patients 
(Carstensen et al., 2010; Feve and Bastard, 2009; Herder et al., 2009; Strandberg et al., 2006). 
Thus, two follow-up studies performed on Whitehall II cohort (UK) identified that systemic 
levels of IL-1Ra are associated with incident type 2 diabetes indicating the complexity of 
immune reactions that support the development of diabetes (Carstensen et al., 2010; Herder et 
al., 2009). In one of these studies it was demonstrated that elevated levels of IL-1Ra can be 
detected 6 years before type 2 diabetes diagnoses (Carstensen et al., 2010). However, the role 
of hyperglycaemia in the induction of IL-1Ra was not considered in these studies. The present 
study for the first time demonstrates that primary human macrophages can respond to 
hyperglycaemia by the production of elevated levels of IL-1Ra. Moreover, hyperglycaemia 
not only increased the levels of IL-1Ra in M2 macrophages, but was also able to increase its 
production in M0 and M1 macrophages, suggesting that hyperglycaemia can induce IL-1Ra in 
chronic inflammatory conditions that precede type 2 diabetes development.  
 
Production of CCL18 in macrophages is highly specifically induced by IL4, and this cytokine 
is one of the most pronounced secreted M2 markers (Kodelja et al., 1998; Kzhyshkowska et 
al., 2016). However, despite being produced by M2 macrophages that primarily function in 
tissue remodelling and healing, overexpression of CCL18 can have detrimental pro-fibrotic 
activities. Increased amounts of CCL18 were identified in alveolar macrophages and 
bronchoalveolar lavage of patients with scleroderma lung disease (Luzina et al., 2002). In a 
mouse model, overexpression CCL18 using adenoviral delivery into the lungs resulted in a 
massive perivascular and peribronchial infiltration of T lymphocytes, destruction of alveolar 
architecture and collagen accumulation (Luzina et al., 2006). It was recently demonstrated 
that secreted levels of CCL18 from white adipose tissue positively correlate with insulin 
resistance (Eriksson Hogling et al., 2016). CCL18 was suggested as a biomarker for diabetic 
nephropathy to monitor treatment efficiency (Tam, 2008). Analysis of the role of CCL18 in 
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the progression of coronary artery disease in patients with cardiac angiography demonstrated 
that increased CCL18 levels were associated with coronary calcification (CAD) (Versteylen et 
al., 2013). In our primary monocytes-based experimental system we demonstrated for the first 
time that hyperglycaemia suppresses the release of CCL18 in M2 macrophages in most of the 
donors analysed. These data suggest that elevated levels of CCL18 in diabetic conditions are 
not a consequence of hyperglycemic activation of macrophages, and other metabolic 
parameters should be considered for the induction of CCL18 production in monocytes and 
macrophages.  
 
Altogether, the analysis of the cytokine release indicated that hyperglycaemia itself, 
independent of other metabolic factors, associated with metabolic syndrome or diabetic 
conditions, can induce a mixed M1/M2 cytokine secretion profile that can support the 
progression of diabetes and vascular complications. Out of four analysed cytokines, IL-1beta 
was the only cytokine for which not only secretion levels, but also gene expression was 
constitutively induced during 6 days of macrophage maturation that suggested a possible 
epigenetic level of expression regulation in hyperglycaemic conditions.  
4.2   Effect of hyperglycaemia on the transcriptional profile of mature M0, 
M1 and M2 macrophages 
To assess the effect of hyperglycaemia on global transcriptional profiles of differentially 
polarised macrophages, the Affymetrix microarray assay was used. Human primary 
monocyte-derived macrophages differentiated for 6 days without stimulation (M0), stimulated 
with IFNg (M1) and stimulated with IL4 (M2) were used for analysis.   
 
Affymetrix microarray expression profiling demonstrated that hyperglycaemia primarily 
influences gene expression in pro-inflammatory M1 macrophages, followed by M0, and has 
only a minor effect on M2 macrophages. In M1 macrophages, 771 genes were upregulated 
and 803 genes were downregulated, in M0, 518 genes were upregulated and 655 genes were 
downregulated, and in M2, 9 genes were upregulated and 7 genes were downregulated. These 
findings were consistent with the major differences in metabolism of M1 and M2 
macrophages, where M1 utilise glucose as an energy source, while M2 utilise fatty acids as an 
energy source (Mills and O'Neill, 2016).  
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The major groups of genes that were upregulated in M0 and M1 macrophages included 1) 
cytokines and chemokine receptors; 2) the RNase A family; 3) the solute carrier family; 4) the 
S100 calcium binding protein family; 5) the transmembrane protein family, and 6) the zinc 
finger family. 
 
Cytokines and their receptors are major regulators of inflammatory processes both on a 
systemic level and during cell-cell communication during the development of diabetes and 
diabetic vascular complications. The strongest effect of hyperglycaemia was found in the 
expression of CCR2, IL-1beta, CSF1R, IL6ST and IL10RA genes. In recent studies in a 
mouse model, it was shown that blockade of CCL2/CCR2 signalling protected from diabetic 
nephropathy (Seok et al., 2013). It was demonstrated that increased levels of secreted IL-1beta 
can predict the development of type 2 diabetes in obese patients (Spranger et al., 2003). 
During pancreatitis, CSF1 dependent macrophages were shown to promote islet angiogenesis 
and maintain beta cell population in a mouse model (Tessem et al., 2008). However, the direct 
effect of hyperglycaemia on the expression of these genes in primary macrophages was 
demonstrated by us for the first time. The role of members of the S100 calcium binding 
protein family in diabetes and vascular complications was also shown previously (Donato et 
al., 2013a). S100 can be produced by neutrophils, macrophages, fibroblasts, osteoblasts and 
melanoma cells (Donato et al., 2013b). It was demonstrated that S100A12 was strongly 
upregulated in diabetic patients (Kosaki et al., 2004). Here for the first time, we found that 
primary macrophages can respond to hyperglycaemia by elevation of S100A9 and S100A12 
expression levels. Hyperglycaemia also stimulated expression of members of the RNase A 
family members including RNASE4, RNASE1, RNASE6 and RNASET2 genes. It was 
recently suggested that the overexpression of RNASEK may mediate the effect of genotype 
on diabetes (Traurig et al., 2016), however, the role of these RNA degrading enzymes in the 
pathogenesis of diabetes remains to be investigated. Hyperglycaemia also stimulated 
expression of members of the solute carrier family group including various types of 
transporters for carnitine fatty acid, sodium bicarbonate, glutamate and the fatty acid 
sodium/myo-inositol. Hyperglycaemia-induced expression of transporters for SLC4A7 
(transporter for sodium bicarbonate), SLC17A7 (transporter for glutamate transport), 
SLC5A3 (sodium/myo-inositol cotransporter), SLC25A20 (transporter for carnitine-fatty 
acid) and SLC27A3 (transporter for fatty acid). Hyperglycaemia also stimulated expression of 
members of the transmembrane protein family groups including TMEM130, TMEM45B, 
TMEM173, TMEM65 and TMEM256. These proteins mainly act as gateways to permit the 
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transfer of specific substances through the membrane. The overexpression of transmembrane 
protein 2 suggests that it can influence the accumulation of lipid droplets in cellular 
triglyceride in fat tissue (Miranda et al., 2014). Hyperglycaemia also stimulated expression of 
members of the zinc finger family groups including ZMYM3, ZNF467, ZNF436, ZNF652 
and JAZF1 genes. These proteins play a role in stabilisation of the fold by coordinating zinc 
ions. It was demonstrated that ZNF236 was strongly upregulated in hyperglycaemia in human 
mesangial cells, suggesting it as a marker for diabetic nephropathy (Holmes et al., 1999).  
  
In order to identify the role of hyperglycaemia in the inflammatory programming of 
macrophages, we focused on the most strongly affected genes from the family of cytokines 
and cytokine receptors: CCR2 and IL-1beta. Since chemokine receptor CCR2 plays an 
important role in trafficking of leukocytes during inflammation and the CCR2/CCL2 axis is 
involved in multiple immunological processes (O'Connor et al., 2015; Yamasaki et al., 2012), 
the role of CCR2 in hyperglycemic conditions was further analysed at the functional 
(migration assay) and epigenetic levels.  
 
4.3  Hyperglycaemia induces CCR2 expression and migration of 
macrophages towards a CCL2 gradient 
Chemokines and cytokines play a role in the pathogenesis of diabetes (Navarro-Gonzalez and 
Mora-Fernandez, 2008; Shanmugam et al., 2003b). CCR2 belongs to the superfamily of the 
G-protein-coupled seven-transmembrane receptors (Sallusto et al., 1998) and is known to 
recruit monocytes to the sites of inflammation through interaction with its ligand CCL2 (Chu 
et al., 2014; Deshmane et al., 2009; Janssen et al., 2002). The effect of diabetic conditions, 
including hyperglycaemia, on CCL2 production and action, was extensively studied. High 
levels of CCL2 were found in many inflammatory conditions, and it is a major 
chemotactic signal for monocytes/macrophages in inflammation (Brodmerkel et al., 
2005). Several studies demonstrated that CCL2 is strongly upregulated by hyperglycemic 
conditions (Panee, 2012; Tesch, 2008; Wood et al., 2014). Several cell types including 
endothelial cells, vascular smooth muscle cells, mesangial cells, fibroblasts and 
pancreatic beta cells were shown to secrete CCL2 (Bertuzzi et al., 2004; Martin et al., 
2008; Monickaraj et al., 2014; Piemonti et al., 2002). It was also shown that human 
pancreatic islets secrete CCL2 during diabetic conditions (Bertuzzi et al., 2004; Martin et al., 
2008; Piemonti et al., 2002). Another study demonstrated that human retinal endothelial cells 
secrete CCL2 during diabetic retinopathy (Monickaraj et al., 2014). Recent studies in a mouse 
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model demonstrated that blockade of CCL2/CCR2 signalling has a protective effect in 
diabetic nephropathy (Seok et al., 2013). However, the role of hyperglycaemia in the 
regulation of CCR2 expression is controversial and can be cell-type specific. Thus, high 
glucose was previously shown to downregulate CCR2 expression in primary human 
mesangial cells (Janssen et al., 2002) and to induce CCR2 expression by podocytes in human 
diabetic nephropathy patients (Tarabra et al., 2009). The results of this study for the first time 
demonstrate that primary human macrophages react to hyperglycaemia by strong upregulation 
of CCR2 expression. Inconsistent with the strong induction of CCR2 expression, 
hyperglycaemia also induced migration of M1 macrophages towards a CCL2 gradient even 
when CCL2 was used in very low concentrations. Therefore, even slight increases of CCL2 
production in hyperglycaemic conditions without any additional strong inflammatory stimuli 
can be sufficient to stimulate migration of M1 macrophages due to their increased sensitivity 
to CCL2 mediated by elevated levels of CCR2. Since CCR2+ macrophages are recognised 
as inflammatory macrophages and positively correlate with the extent of inflammation 
(Weisberg et al., 2006), it was hypothesised that hyperglycaemia skews macrophages 
towards a pro-inflammatory state and may favour their enhanced migration in the areas 
of diabetes-related inflammation and in fat tissues. Since pancreatic islets secrete CCL2 
(Martin et al., 2008) that may attract pro-inflammatory M1 macrophages leading to the 
destruction beta cells, it would be a promising approach to block the CCR2 receptor to 
attenuate M1 macrophage migration into pancreatic islets or fat tissues. Of note, it was 
previously shown that CCR2 antagonist treated macrophages significantly decreased 
migration towards CCL2 in vitro (Lee et al., 2010). The results of the current study suggested 
that, in perspective, CCR2 antagonists may be used to attenuate migration of CCR2 
expressing macrophages in the areas of inflammation in diabetic patients.  
4.4 Epigenetic regulation of CCR2 and IL-1beta expression 
Several studies showed that gene expression in macrophages is regulated on the epigenetic 
level in the inflammatory conditions (Amit et al., 2016; Kapellos and Iqbal, 2016a; Lavin et 
al., 2014). Evidence accumulates demonstrating that epigenetic factors regulate gene 
expression in endothelial cells, vascular smooth muscle, retinal and cardiac cells in diabetic 
conditions (Reddy et al., 2013; Reddy et al., 2015; Villeneuve et al., 2011). In the current 
study, the hypothesis about the hyperglycaemia-mediated regulation of the expression of pro-
inflammatory genes CCR2 and IL-1beta was tested experimentally. Bioinformatic analysis of 
CCR2 and IL-1beta promoters using Roadmap Epigenomics Visualization Hub (VizHub)) 
was used to select the histone marks. Three activating histone marks (H3K4me1, H3K4me3 
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and acetylated H3) and 2 repressing histone marks (H3K9me3 and H3K27me3) were selected 
for chromatin immunoprecipitation experiments.  
Epigenetic level of regulation for CCR2 gene expression was previously demonstrated in 
limbic forebrain in mice treated with methamphetamine (Ikegami et al., 2010). In the present 
study, it was shown for the first time that hyperglycaemia induces the presence of activating 
histone marks (H3K4me1, H3K4me3 and AceH3) on the CCR2 promoter associated with 
increased expression of the CCR2 gene. Remarkably, two elevated level histone marks 
(H3K4me1 and H3K4me3) were found to be sufficient to increase the expression of the 
CCR2 gene. These results are comparable with the study in a mouse model used by Ikegami 
et al. where up-regulated CCR2 gene expression was shown to be accompanied by a 
significant increase in histone H3 lysine 4 (H3K4) trimethylation (Ikegami et al., 2010).  
IL-1beta is a critical factor produced by M1 macrophage conditions and involved in the 
detrimental effects (Gao et al., 2014). Epigenetic regulation of IL-1beta DNA methylation 
was demonstrated in human articular chondrocytes (Hashimoto et al., 2009). It was also 
demonstrated that association of H3 serine10 phosphorylation on the IL-1beta promoter 
correlates with gene expression in LPS stimulated THP-1 cells during sepsis (Yoza and 
McCall, 2011). In this study, it was shown that the control of IL-1beta gene expression in M1 
macrophages by hyperglycaemia is regulated through activating histone modifications 
H3K4me1, H3K4me3 and AceH3. Overall, the current study for the first time demonstrates 
that hyperglycaemia induces the association of activating histone marks with promoters of 
CCR2 and IL-1beta genes in primary human macrophages.  
Each specific histone modification is mediated by an enzyme called transferases (for example, 
methyltransferases, acetyltransferases) (Arrowsmith et al., 2012). Several groups have 
demonstrated that SET7, the methyltransferase responsible for mono-methylation of H3K4, 
can mediate vascular damage in hyperglycaemic conditions (El-Osta et al., 2008; Li et al., 
2008; Okabe et al., 2012; Paneni et al., 2015; Sun et al., 2010). It was shown that 
hyperglycaemia induces SET7 translocation into the nucleus of human endothelial cells 
(Okabe et al., 2012). Furthermore, it was demonstrated that hyperglycaemia-induced 
overexpression of pro-inflammatory cytokine IL8 requires functional SET7, since this effect 
was abrogated in SET7 knockdown endothelial cells. The active role of SET7 in 
hyperglycaemia-induced upregulation of IL8 expression was confirmed by the fact that 
hyperglycaemia increased monomethylation of H3K4 on the IL8 promoter in endothelial cells 
(Okabe et al., 2012). The study of Paneni et al. demonstrated that increased levels of SET7 
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transcripts were found in peripheral blood mononuclear cells isolated out of patients with type 
2 diabetes compared with healthy controls that correlated with the monomethylation of H3K4 
on the NF-kB promoter (Paneni et al., 2015). SET7/9 was also shown to be involved in the 
upregulation of inflammatory genes (TNF-alpha and CCL2) in macrophages from diabetic 
mice (Li et al., 2008). However, the direct effect of hyperglycaemia on the activation of SET7 
in primary human monocytes was not demonstrated to date. The identified by us effect of 
hyperglycaemia on the increased association of H3K4me1 with promoters of inflammatory 
genes is consistent with the data obtained on endothelial and mononuclear cells. Moreover, 
for the first time, we demonstrated that hyperglycaemia induces increased association of 
H3K4me1 with promoters of CCR2 and IL-1beta in mature human macrophages. The role of 
SET7 in the monomethylation of H3K4 on CCR2 and IL-1beta in primary monocyte-derived 
macrophages in hyperglycaemic conditions remains to be identified. 
Tri-methylation of H3K4 is mediated by another group of enzymes, MLL (Mixed lineage 
leukaemia) (Ruthenburg et al., 2007). MLL regulates mainly HOX gene (genes involved in 
embryogenesis) (Milne et al., 2002). The function of MLL was mainly studied in the context 
of leukaemia (Milne et al., 2002; Zhu et al., 2016). However, the effect of hyperglycaemia on 
the activation of MLL was not demonstrated to date. Identified in the current study, the effect 
of hyperglycaemia on the increased association of H3K4me3 with promoters of CCR2 and 
IL-1beta suggests the involvement of MLL enzymes in hyperglycaemia-mediated pro-
inflammatory activation of different cell types. Evidence accumulates indicating that 
epigenetic editing (writers or erasers) can be used to target endogenous gene expression (de 
Groote et al., 2012). Currently, new strategies are under development based on the targeting 
of histone modifying enzymes to modulate gene expression for therapeutic purposes, while 
such strategies were mostly suggested for treatment of cancer (Altucci and Rots, 2016). In 
future, epigenetic editing can be a powerful tool to target gene expression of CCR2 to prevent 
the accumulation of M1 macrophages in pre-diabetic or diabetic lesions.   
 
In summary, we found that hyperglycaemia-induced expression of CCR2 and IL-1beta on 
primary human macrophages is linked to the epigenetic modifications of the CCR2 and IL-
1beta promoters by activating the histone code. Elevated levels of CCR2 resulted in a high 
sensitivity of macrophages to the chemotactic ligand CCL2. Our data suggest that 
hyperglycaemia can be a primary factor that induces attraction of pro-inflammatory 
macrophages into the sites of low grade inflammation that can affect the progression of 
vascular complications at very early stages. 
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5. Summary 
Hyperglycaemia is the hallmark of diabetes that is related to the development of diabetic 
vascular complications. Macrophages are key innate immune regulators of inflammation that 
undergo two major vectors of functional polarisation: classically (M1) and alternatively (M2) 
activated macrophages. Both M1 and M2 types of macrophages play a role in diabetes. M1 
are involved in the establishment and progression of insulin resistance and inflammatory 
processes leading to vascular complications, whereas M2 can have protective effects in 
diabetes by reducing inflammation, obesity and insulin resistance. However, the effect of 
hyperglycaemia on differentiation and functional programming of macrophages is poorly 
understood. In order to analyse the detrimental effects of high glucose on the differentiation 
and activation of monocytes and macrophages, we established a new model system based on 
primary human monocyte-derived macrophages cultured in serum-free conditions in the 
presence of 5mM and 25mM glucose. The effects of high glucose were examined in control 
(M0), classically (M1) and alternatively (M2) activated macrophages. Using RT-PCR and 
ELISA, the expression and release of TNF-alpha and IL-1beta (M1 cytokines) and IL-1Ra 
and CCL18 (M2 cytokines) were quantified. Hyperglycaemia stimulated the production of 
TNF-alpha, IL-1beta and IL-1Ra during macrophage differentiation. The effect of 
hyperglycaemia on TNF-alpha was acute, while the stimulating effect on the production IL-
1beta and IL-1Ra was continuous during monocyte to macrophage differentiation. Production 
of CCL18 was suppressed in M2 macrophages by hyperglycaemia. Altogether, analysis of the 
cytokine release indicated that hyperglycaemia itself, independent of other metabolic factors, 
can induce a mixed M1/M2 cytokine secretion profile that can support the progression of 
diabetes and vascular complications. In order to identify differentially expressed genes in M0, 
M1 and M2 macrophages differentiated in normal and high glucose conditions, an Affymetrix 
DNA microarray was used. We found that hyperglycaemia-induced differential expression of 
1171 genes in M0, 1573 genes in M1 and 16 genes in M2. The major affected groups of 
differentially expressed genes were: chemokines, cytokines, chemokine receptors, the 
glycoproteins family, the RNase A family, the S100 calcium binding protein family, the 
solute carrier family, the transmembrane protein family and the zinc finger family. 
Hyperglycaemia had a very strong inducing effect on the expression of CCR2, a major 
receptor for macrophage chemotactic factor CCL2 that mediates recruitment of macrophages 
in chronic inflammation. The ability of hyperglycaemia to enhance the trans-migratory 
activity of macrophages was analysed in a trans-well system. Significantly higher amounts of 
M0 (7.6 times increase) and M1 (11.2 times increase) transmigrated towards CCL2 (100 
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ng/ml) in hyperglycaemic conditions. In consistency with the strong induction of CCR2 
expression, hyperglycaemia also induced migration of M1 macrophages towards CCL2 even 
when it was used in very low concentrations (up to 1.56 ng/ml). 
 
The histone code was demonstrated to be an essential mechanism that controls macrophage 
differentiation in inflammatory conditions. However, the role of the histone code in the 
hyperglycaemia-mediated programming of human macrophages remained unknown. The 
chromatin immunoprecipitation assay (ChIP) was applied to examine the presence of histone 
marks on the promoters of these genes. Three active histone modifications (acetylation of 
histone H3(aceH3), H3K4me3 and H3K4me1) and two repressive histone modifications 
(H3K9me3 and H3K27me3) at the promoters of CCR2 and IL-1beta genes were analysed in 
primary human macrophages cultured in normal and hyperglycaemic conditions. It was 
demonstrated that hyperglycaemia caused a statistically significant increase in the level of 
histone activating marks H3K4me1 and H3K4me3 at the CCR2 promoter and IL-1beta 
promoters. Hyperglycaemia did not affect repressing histone marks on the CCR2 and IL-
1beta gene promoters. Analysis of macrophages isolated from individual donors demonstrated 
that levels of activating histone marks on CCR2 and IL-1beta promoters corresponded to the 
level of up-regulation of their gene expression. The cooperation of H3K4me1, H3K4me3 and 
AcetylH3 was required for efficient stimulation of CCR2 gene expression, while cooperation 
of H3K4me1 and H3K4me3 was critical for stimulation of IL-1beta gene expression in 
hyperglycemic conditions. Tri-methylation of H3K4 is mediated by the MLL group of 
enzymes, and our study, for the first time, suggests that MLL enzymes can be involved in the 
hyperglycaemia-mediated epigenetic programming of macrophages.  
 
In summary, we found that hyperglycaemia-induced expression of CCR2 and IL-1beta on 
primary human macrophages is linked to epigenetic modifications of CCR2 and IL-1beta 
promoters by activating the histone code. Elevated levels of CCR2 resulted in a high 
sensitivity of macrophages to the chemotactic ligand CCL2. Our data suggest that 
hyperglycaemia can be a primary factor that induces attraction of pro-inflammatory 
macrophages into the sites of low-grade inflammation that can affect the progression of 
vascular complications at very early stages. 
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